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ABSTRACT 
Cholesterol 24-hydroxylase (CYP46A1) belongs to the cytochrome P450 super family 
and is responsible for conversion of cholesterol to the oxysterol 24S- 
hydroxycholesterol (24S-OHC). This structural modification allows 24S-OHC to 
traverse the blood brain barrier and this pathway is the major one for elimination of 
cholesterol from the mammalian brain. CYP46A1 is almost exclusively located to 
neurons in the brain and retina.  The promoter region of CYP46A1 shows classical 
hallmarks of a gene with putative housekeeping function. Oxidative stress was the only 
factor initially shown to cause signi¿cant increase in CYP46A1 reporter activity.  
The aim of this thesis was to obtain a more profound knowledge about regulation of 
CYP46A1 and the regulatory importance of its product. In addition the possibility was 
investigated that the levels of 24S-OHC in cerebrospinal fluid may be used 
diagnostically.  
 
In paper I we tested the possibility that epigenetic factors are important for CYP46A1 
expression. We could demonstrate both in vivo and in vitro that the histone deacetylase 
inhibitors Valproate and Trichostatin A induce the expression of CYP46A1, essentially 
reprogramming non-neuronal cells to express CYP46A1 to the same level as that found 
in adult neurons. 
In paper II we investigated the inhibitory effect of the antifungal drug Voriconazole on 
CYP46A1 in mice and we hypothesised that inhibition of CYP46A1 may have a role in 
the reported side effects in connection with Voriconazole (neurological and visual 
disturbances). A decrease in concentration of 24S-OHC in the mouse brain and a 
reduction in the lathosterol:cholesterol ratio, an index of brain cholesterol synthesis, 
was demonstrated . 
In paper III we investigated the effect of omega-3 polyunsaturated fatty acids in 
Syrian Hamsters. Enrichment of diet with omega 3-fatty acids resulted in increased 
CYP46A1 mRNA levels in the brain.  
In paper IV we investigated the consequences of an overexpression of CYP46A1. A 
transgenic mouse model overexpressesing human CYP46A1 was developed and 
characterized.  Significant expression of the human CYP46A1 protein was found in 
brain, testis and eye and the brain in which contained more than 10-fold higher levels 
than the other organs. Circulating levels of 24S-OHC were increased by 4-6 fold and 
the fecal excretion of this steroid in free form was increased more than 20 fold. In the 
brain of the transgenic mice the total amount of CYP46A1 protein was increased 2-4 
fold and had similar cellular distribution to the endogenous enzyme. The level of 24S-
OHC in the brain was about double compared to the controls. It is known that 24S-
OHC is an efficient ligand for the liver X receptor (LXR) in vitro. The overproduction 
of 24S-OHC did not significantly activate any LXR target genes in the brain, while in 
the liver some of these genes were affected but not in the direction expected in 
connection with LXR activation.  
Based on in vitro studies a regulatory link between 24S-OHC and APOE has been 
suggested and addition of 24S-OHC stimulates secretion of APOE from cultured 
astrocytes. In paper V we investigated if there is a correlation between the 
concentration of APOE and 24S-OHC in cerebrospinal fluid in patients. A significant 
  
correlation was found in patients with Alzheimer’s disease (AD) and mild cognitive 
impairment (MCI), but not in the control group. 
In paper VI we investigated the possibility that the level of 24S-OHC in cerebrospinal 
fluid may be an early biomarker for AD. We could show that 24S-OHC is as sensitive 
as the standard diagnostic biomarkers for AD (tau-protein, phospho-tau, and beta 
amyloid). Interestingly 24S-OHC appeared to be a more sensitive marker for MCI than 
the standard biomarkers. 
 
According to current concepts the levels of cholesterol in critical neuronal membranes 
is of importance for the balance the between Į- and ȕ- secretase pathway. An increased 
consumption of this cholesterol by increased activity of CYP46A1 would be expected 
to favour the Į-secretase pathway and reduce amyloid formation. Under in vitro 
conditions 24S-OHC seems to have a direct inhibitory effect on amyloid formation. 
The mouse model with overexpressed CYP46A1 presented in paper IV will be ideal to 
test the hypothesis that an upregulation of CYP46A1 is neuroprotective and reduces 
amyloid formation. As shown in paper I histone deacetylase inhibitors are potential 
drugs to reach this goal. High intake of omega-3 fatty acids seems to have some 
neuroprotective effects in humans and the results shown in paper III is consistent with 
the possibility that part of this may be mediated by an effect on CYP46A1. Inhibition of 
CYP46A1 would be expected to have a negative effect on the function of the central 
nervous system and possibly also retina. The results of paper II demonstrated that the 
drug Voriconazole, with known negative side effects on CNS and visual function, 
inhibits the flux in the mevalonate pathway in the brain. In part this may be the 
consequence of inhibition of CYP46A1. Results are presented to indicate that the levels 
of 24S-OHC in cerebrospinal fluid may be used as diagnostic tool in connection with 
neurodegeneration (paper V and VI).  
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INTRODUCTION 
Milestones in the history of cholesterol 
 
The French chemist Michel Eugène 
Chevreul is accredited with the initial 
isolation of cholesterol (Fig. 1) in 
1815, but it was not until 1888 that 
the empirical formula C22H46O was 
established by Reinitzer. The correct 
chemical structure of the molecule 
was discovered by Wieland and Dane 
in 1932. However, already in 1834, 
Couerbe recognized the importance of cholesterol in the nervous system (1, 2).  
Cholesterol is the molecule most decorated by Nobel prizes, the most recent of which 
was awarded to Michael S. Brown and Joseph I. Goldstein in 1985 for their discoveries 
concerning the regulation of cholesterol metabolism. We have come a long way in 
understanding the biology of this molecule and one can only be astonished by the 
endless discoveries that have been revealed since the discovery of cholesterol.  
Considerably less is known about cholesterol turnover in the brain than in other organs. 
 
Biological roles of Cholesterol  
Cholesterol is a multi-functional molecule. Among its many functions it acts as a 
precursor for steroid hormones and bile acids. It is also a critical component of cellular 
membranes where it affects membrane fluidity. Cholesterol homeostasis must be tightly 
controlled throughout the organism to avoid excess deposition or decreased synthesis 
and this is particularly the case in the brain. Cholesterol has a pivotal function in the 
central nervous system (CNS) where it serves as a critical component of the myelin 
sheath and is involved in synapse formation. (2). 
 
The myelin is important for action potential velocity. The evolutionary adaption of the 
cholesterol–rich plasma membrane to form compact myelin made it possible to “wire” 
the complex brain to a very condensed structure with relatively small axon diameter.   
Cholesterol is also important for the normal development of the brain and is critical for 
the correct targeting of the morphogenic factor Sonic hedgehog which drives the 
expansion of the largest neuronal population in the brain. Inhibition of  Sonic hedgehog 
leads to abnormal brain development (3). 
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     Synthesis of cholesterol 
A normal healthy adult synthesizes approximately 1g of cholesterol every day and 
consumes about 0,4-0,5 g/day (4). A constant level of cholesterol in human plasma of 
about 1,5-2,0 g/L (4-5mM) is maintained by control of its synthesis as well as its uptake 
and metabolism. The level of cholesterol is influenced to a small degree by the dietary 
intake of cholesterol. Newly synthesized cholesterol is used in the formation of 
membranes and in the synthesis of steroid hormones and bile acids (4). 
Biosynthesis of cholesterol requires large amounts of energy and involves numerous 
enzymes in the cytosol and the endoplasmic reticulum (ER). Cholesterol is made from 
Acetyl-CoA in four stages: 1) condensation of three acetate units to form a six-carbon 
intermediate, mevalonate; 2) conversion of mevalonate to activated isoprene units; 3) 
polymerisation of five-carbon isoprene units to form squalene; and 4) cyclization of 
squalene to form the four rings of the steroid nucleus, followed by a series of oxidations, 
reductions and removal of methyl groups which lead to cholesterol formation. The rate-
limiting step in the pathway to cholesterol is the conversion of 3ȕ-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a reaction catalyzed by the 
microsomal HMG-CoA reductase (HMGCR) that can be inhibited by statins (5). Sterol 
regulatory element binding proteins (SREBP) are a family of transcription factors that 
regulate cellular cholesterol and fatty acid homeostasis by responding to the cellular 
levels of free cholesterol. SREBPs bind as dimers to Sterol Regulatory Elements (SREs) 
in the promoter region of a large number of genes resulting in increased transcription. 
There are three SREBP isoforms: SREBP-1a, 1c and 2.  The first two SREBPs are 
thought mainly to regulate the genes involved in fatty acid synthesis whereas SREBP-2 
mainly regulates the genes involved in cholesterol biosynthesis. SERBP-1a is believed 
to activate genes in both processes. SREBP-2 activates its own transcription in 
combination with another transcription factor, nuclear factor Y. In the regulation of 
cholesterol synthesis SREBP interacts with two other proteins, insulin induced protein 
(INSIG) and SREBP cleavage activating protein (SCAP).  
SCAP is a membrane bound protein that has a sterol sensing domain similar to that in 
HMGCR. In the presence of high concentrations of cholesterol SREBP remains bound 
to the ER through an INSIG-1: SCAP complex. Decreasing cholesterol levels lead to a 
conformational change in SCAP which results in release of INSIG-1. This is the 
consequence of enzymatic cleavage of SREBP in the SCAP: SREBP-2 complex in a 
two-step process by two membrane bound proteases, site 1 protease and site 2 protease. 
The released amino-terminal active form of SREBP-2 then moves to the nucleus and 
binds to promoters containing SREs (6-9).  
 
HMGCR can also be regulated by phosphorylation and dephosphorylation. The enzyme 
is most active in its unmodified form and phosphorylation of the enzyme decreases its 
activity. HMGCR is phosphorylated by adenosine monophosphate activated protein 
kinase, AMPK. The activity of HMGCR is additionally controlled by the cyclic 
adenosine monophosphate signalling pathway. Increase in cAMP leads to activation of 
cAMP-dependent protein kinase. Since the intracellular level of cAMP is regulated by 
hormonal stimuli, regulation of cholesterol biosynthesis is hormonally controlled to 
some extent (10).  
The ability of insulin to stimulate, and glucagon to inhibit HMGCR activity is consistent 
with the effects of these hormones on other metabolic pathways.  
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Long-term control of HMGCR activity is exerted primarily through control over the 
synthesis and degradation of the enzyme. When levels of cholesterol are high, the level 
of expression of the HMGCR gene is reduced. Conversely, reduced levels of cholesterol 
activate expression of the gene. Insulin also regulates cholesterol metabolism by 
increasing the level of HMGCR synthesis. HMGCR is localized to the ER and like 
SCAP contains a sterol-sensing domain. High sterols levels cause the INSIG proteins to 
bind to HMGCR sterol-sensing domain; an ubiquitin ligase (gp78) is recruited to the ER 
and ubiquitinates HMGCR and targets it for the proteasome, a multiprotein complex 
dedicated to protein degradation (11). The primary sterol regulating HMGCR 
degradation appears to be cholesterol itself. As the levels of free cholesterol increase in 
cells, the rate of HMGCR degradation increases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overview of cholesterol biosynthesis (12). Note that each arrow is actually several steps 
and the branch pathways are omitted for clarity. 
 
Cholesterol absorption, transport and metabolism to bile acids 
The cholesterol in the diet is absorbed from the intestine and ultimately delivered to the 
liver by chylomicrons. In the liver cholesterol can be converted to bile acid or secreted 
to extrahepatic tissues as very low density lipoproteins (VLDL). VLDL are remodeled 
by the action of lipoprotein lipase that removes core triacylglycerol molecules and 
Apolipoprotein A  (APOA1) and Apolipoprotein C (APOCI and ACPOCII) from 
VLDL to high density lipoprotein (HDL). Ultimately this process results in the 
formation of a low density lipoprotein (LDL) particle which can supply peripheral 
tissues with cholesterol.  The cellular LDL intake is tightly regulated via the LDL 
receptor (LDLR) and Apolipoprotein B (APOB). The influx of cholesterol inhibits 
HMGCR and cholesterol synthesis, and upregulates cholesterol esterification by acyl-
CoA:cholesterol Acyl transferase (ACAT1). Reverse cholesterol transport, by which 
cells from different organs eliminate excess cholesterol is mediated by HDL. The HDL 
particles contain APOA1 which can extract cholesterol directly from the plasma 
membrane. This transfer is facilitated by members of the ATP binding cassette (ABC)-
transporter family.  
About 1g of cholesterol is eliminated from the body every day.  Approximately half of 
this is excreted into the feces after being converted to bile acids. The bile acids formed 
Statins
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play an important role in solubilisation and absorption of fats, cholesterol, lipophilic 
vitamins and certain drugs. There are two major pathways of bile acid synthesis: the 
neutral pathway is initiated by the rate-limiting enzyme cholesterol 7Į-hydroxylase, 
(CYP7A1) whereas the alternative or acidic pathway is initiated by the enzyme sterol 
27-hydroxylase (CYP27A1). Under normal conditions the neutral pathway dominates 
in healthy adult humans (13). In humans the bile acid pool consists of the primary bile 
acids cholic acid (CA) and chenodeoxycholic acid (CDCA) and also the secondary bile 
acids deoxycholic acid (DCA) and lithocholic acid. CA is considered to be a product of 
the classic pathway whereas CDCA is the major end product of the alternative 
pathway.   
In addition to this the liver can eliminate cholesterol through excretion of free 
cholesterol in bile via the transporters ABCG5 and ABCG8. Disruption in the latter 
transport system leads to severe sitosterolemia and patients with this condition have an 
accumulation of plant sterols and an increased risk of atherosclerosis. Activation of 
ABCG5/G8 transcription by the nuclear receptor liver X receptor (LXR) results in 
increased cholesterol excretion (14).                                                 
Cholesterol in CNS 
Cholesterol has an important role in connection with brain development and function. 
Cerebral cholesterol represents 2-3% of the wet weight of the brain, corresponding to 
about 25% of the total amount of cholesterol present in humans. The cholesterol content 
of the brain is independent of the dietary uptake and hepatic synthesis and there is solid 
evidence that almost all of it is produced in situ. Brain cholesterol is isolated from other 
pools of cholesterol by the blood-brain barrier (BBB)(2,15,16). The synthesis of 
cholesterol during the development of the central nervous system is relatively high but 
declines to very low levels in the adult stage (16). This is possible due to the efficient 
recycling of the brain cholesterol. As a consequence of this, and the fact that myelin is 
almost excluded from the general metabolism, brain cholesterol has an extremely long 
half-life(2). Despite this efficient mechanism of reutilization, there are specific pathways 
for cholesterol elimination from the brain. It has been estimated that 1-2 mg cholesterol 
may be eliminated from the brain via the cerebrospinal fluid (CSF) in  apolipoprotein E 
(APOE) containing lipoproteins each day as part of normal CSF turnover (2). About 6-7 
mg is eliminated by the 24S-hydroxylase (CYP46A1) pathway (cf. below) 
In the CNS cholesterol is present in 2 major pools; myelin cholesterol that is a product 
of oligodendroglia and cholesterol present in plasma membranes of astrocytes and 
neurons (16).   
The astrocytes are believed to be responsible for most of the synthesis of cholesterol 
required for the neurons. They secrete cholesterol in APOE containing lipoproteins. 
ABCA1 is a monomeric transporter that resides in the plasma membrane of tissues 
including liver, intestine, placenta, adipose, spleen and brain. It transports phospholipids 
and cholesterol while (ABC binding cassette gene 1) ABCG1 has been implicated in 
intracellular trafficking of sterols in macrophages (14). Astrocytes also synthesise and 
secrete APOE. This process has been shown to be stimulated by 24S-OHC. In the 
present work we study the possibility that there is a relation between 24S-OHC and 
APOE in CSF (paper IV). 
APOE-bound cholesterol enters the neurons via the LDLR. Once in the cell cholesterol 
passes the post-lysosome, late endosome system via the Niemann-Pick type C (NPC) 
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proteins type 1 (NPC1) and 2 (NPC2). NPC1 is a large membrane that localizes in the 
endosome and NPC2 is a small luminal protein that binds cholesterol with high affinity. 
Cholesterol can then be transported to the plasma membrane via vesicular transport or 
delivered to organelles (17). 
Cholesterol is converted into 24S-OHC via CYP46A1 in the neurons. In contrast to 
cholesterol this monooxygenated molecule is able to traverse the BBB (2, 19). It has 
been shown that elimination of cholesterol from the brain of rats (20) and mice (21) 
corresponds to about 2/3 of the cholesterol synthesis in this organ. 
 
24S-OHC and other oxysterols are ligands of the LXR, a class of nuclear hormone 
receptors (22), which translocate to the nucleus and may induce expression of both 
APOE and ABCA1 genes in astrocytes (18). LXR subtypes are important components 
of a complex regulatory system that senses cholesterol levels and modifies gene 
expression accordingly (22). The isoforms LXRĮ and ȕ have been identified and are 
known to be activated by oxysterols in vitro. LXRĮ  is restricted to certain tissues and  
LXR ȕ  is more generally expressed. LXR target genes include ABCA1 and ABCG1, 
and SREBP1.  
In the CNS both of the isoforms are expressed and believed to be involved in the brain 
cholesterol metabolism. LXR ȕ levels are 2-5 folds higher in the brain than in liver. 
Levels of LXRĮ in cultured neurons and glia are 2% and 17% compared to the liver, 
and that for LXR ȕ are 110% and 380%, respectively (23). 
LXR double knock-out mice show a variety of CNS defects upon aging including lipid 
accumulation, astrocyte proliferation, and disorganization of the myelin sheaths.  Both 
cholesterol and APOE are crucial for control of synaptic function. A normal cycle of 
cholesterol biosynthesis, transport, and turnover is required for normal synapse 
formation, stabilization, function and plasticity. 
Neuronal cells seem to be dependent upon a flux of cholesterol from astrocytes (24). 
Based on in vitro experiments the possibility has been suggested that this flux may be 
regulated by 24S-hydroxycholesterol (24S-OHC) (Fig 3). 
If the relation between Apo E and 24S-OHC suggested by the in vitro experiments by 
Pfrieger (24) and Abildayeva et al. (18) is of importance under in vivo conditions a 
relation between these compounds may be expected in CSF. This possibility was 
studied in paper V. 
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Figure  3.  Suggested interaction between astrocytes and neuronal cells in cholesterol 
homeostasis modified according to Pfrieger (24) and Abildayeva et al (18). The neuronal cells are 
dependent on astrocytes for delivery of cholesterol. Excess cholesterol may be eliminated 
through the 24S-hydroxycholesterol mechanism. 24S-hydroxycholesterol is a potent activator of 
the nuclear receptor LXR. The latter activation may lead to increased activation of the cholesterol 
transporter ABCA1. 
 
Lipoproteins 
In the aqueous environment of the blood, neutral lipids circulate packaged as 
lipoproteins. Lipoproteins are composed of phospholipids and free cholesterol shell 
surrounding a triglyceride (TG) and cholesteryl-ester (CE) core. Lipoproteins are 
stabilized by surface lipoprotein and are ligands for lipoprotein receptors. Plasma 
lipoproteins are generally separated by size and density in four major classes that vary in 
their core TG/CE content and apoprotein composition: Chylomicrons, VLDL, LDL and 
HDL (25). 
In the CNS including CSF the lipoproteins have a density similar to HDL, with a core of 
lipid and esterified CE. CSF lipoproteins are categorized by apolipoprotein into APOE, 
A-I, A-IV, APOD, APOH and APOJ (26, 27). APOE is the dominant apolipoprotein in 
the brain. 
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Apolipoprotein E 
APOE was recognised in 1973 as part of triglyceride-rich lipoprotein complexes and it 
was shown to be important for cholesterol transport. APOE is expressed in several 
organs, with the highest expression in the liver followed by the brain (28). Astrocytes 
and to some extent microglia, are the major cell types expressing APOE (29-31). In 
humans the APOE genes show polymorphism with three different alleles (İ2, İ3 ,İ4) on 
chromosome 19, which give rise to six different phenotypes (E2/2, E2/3, E2/4, E3/3, 
E3/4 and E4/4).  
The APOE isoforms differ only by a single amino acid substitution of Cys to Arg at 
position 112 and 158 (32) leading to different biological properties (33). APOE 3 is the 
most common isoform (77-78%) in the general population while APOE2 is found in 7-
8% and APOE4 in 14-16% of individuals (34, 35). After findings of immunoreactivity 
of APOE in the amyloid plaques (36) the APOE4 allele was discovered to be the most 
important genetic risk factor for sporadic Alzheimer’s disease (AD) (32, 37). In contrast, 
the APOE2 allele has been associated with a lower risk for AD (38). Amyloid beta (Aȕ) 
is formed by proteolytic cleavage of the amyloid precursor protein (APP) and plays an 
important role in the AD pathology. There is evidence suggesting that APOE4 is 
somehow involved in the Aȕ formation. As mentioned above, APOE is present in the 
neuritic plaques and it has been reported that Aȕ levels are elevated in brains of AD 
patients carrying APOE4 allele. It is not yet known if APOE4 has an active role in 
aggregation and/or deposition of Aȕ. APOE4, in a lipid- free form has a greater avidity 
to Aȕ than APOE3 (34, 39, 40).  Post mortem studies have shown increased Aȕ 
deposition in APOE4 carriers both in sporadic and genetic AD cases (39, 41). Hyper-
phosphorylation of microtubule-associated protein known as tau protein leads to 
insoluble aggregation and form neurofibrillary tangles in the neuronal cells. This is 
common in connection with neurodegenerative diseases, in particular AD. Different 
APOE isoforms may influence formation of tau. In vitro studies have shown that 
APOE3 forms a stable complex with tau. The interaction between APOE3 and tau was 
prevented by phosphorylation of tau, suggesting that APOE3 preferentially binds to 
nonphosphorylated tau (42). However there is no evidence demonstrating localization of 
APOE to the neuronal cytosol, where the majority of tau exists under normal conditions 
(29, 43). In the peripheral nervous system and CNS the levels of APOE increases 
following neuronal injuries. It has been suggested that this increase may be required for 
repair of the nervous system by redistribution of lipids and cholesterol for membrane 
repair and synaptic plasticity. Most studies have shown that APOE3 augment neurite 
outgrowth to a greater extent than APOE4 (29, 44). The effect of APOE2 has not yet 
been fully examined in connection to neurite sprouting.  
 
Other lipoproteins in the brain  
In addition to APOE and APOAI, APOJ and APOD are important lipoproteins in the 
brain. Interestingly the apolipoproteins appear to have overlapping functions. A 
knockout of APOE results in a marked compensatory increase in levels of APOD (45). 
 
APOJ is a 70kDa protein associated with HDL in human plasma. This multifunctional 
ubiquitous protein has been purified from several tissues (46-48). The adult brain is a 
major site of APOJ mRNA synthesis in several mammalian species (46, 47, 49, 50). 
This lipoprotein has been associated with many different injuries and chronic 
inflammation of the brain including Multiple Sclerosis (51), Huntington disease (52) and 
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AD (53). Experimental brain lesions induce a marked increase of APOJ in neurons. 
Aging appears to up-regulate the expression in neurons (54). In AD increased levels of 
hippocampal and cortical APOJ mRNA and protein have been reported (55). APOJ has 
been suggested to have several neuroprotective properties: 1) direct neuroprotection, 
through the triggering of signalling cascades that affect neurodegenerative pathways and 
apoptotic processes; 2) indirect neuroprotection, through its interaction with Aȕ peptides 
and 3) neurotrophic functions, promoting general recovery from neuronal injury via 
lipid transport or membrane recycling (46, 56). 
 
APOD is a secreted glycoprotein assigned with many putative functions including lipid 
transport. Human APOD was first identified in plasma HDL (57). In humans, its main 
sites of expression are the brain and testes. In the CNS, it is mainly expressed in glial 
cells (both astrocytes and oligodendrocytes) and their precursors, (58) but in pathological 
situations it can also be expressed in neurons. The protein itself is small (18 kD), soluble  
and has no homology to other apolipoproteins (59). Elevated levels of APOD have been 
described in association with various neurological disorders, including AD, Parkinson’s 
disease and stroke. (59)  
Since APOD is a lipid carrier, it is particularly interesting to observe its upregulation in 
disorders of the myelin. One of the most striking increases is observed in regenerating 
and remyelinating sciatic nerve, in the rat. After 3 weeks post-crush injury, APOD 
increases 500-fold at the site of the lesion, and remains elevated while regeneration takes 
course. (60) 
 
Side-chain oxidized oxysterols 
Oxysterols were first recognized by Lifschütz 100 years after the actual discovery of 
cholesterol. They are defined as mono-oxygenated derivatives of cholesterol. Several 
cytochrome P450 enzymes are involved in the formation of particular 
hydroxycholesterols. CYP46A1 is a microsomal enzyme present in neurons and 
produces 24S-OHC which is also called cerebrosterol, because of its abundance in brain.  
The mitochondrial enzyme CYP27A1 is responsible for the formation of 27-
hydroxycholesterol (27-OHC) which is an intermediate in bile acid synthesis and is the 
major oxysterol in the human circulation.   
In contrast to cholesterol the side chain oxidized oxysterols are able to traverse the BBB.  
The cross-over is dependent on the presence of a hydroxyl group in the side-chain of 
cholesterol leading to re-arrangement of membrane phospholipids in a way that is more 
favourable from an energy point of view to expel the oxysterol. Due to this, the flux of a 
side-chain oxidized oxysterol across a biomembrane may be three orders of magnitude 
faster than that of cholesterol. Most oxysterols have a short half-life because of the rapid 
conversion into bile acids and final elimination in the liver. The net efflux of 24S-OHC 
from the brain has been determined to be about 6-7mg per 24 hours (61).There is a 
corresponding uptake of the latter oxysterol from the liver. This demonstrates that the 
brain is the major source of the 24S-OHC present in the circulation. 
Oxysterols are able to regulate the expression of many genes involved in lipid 
biosynthesis, at least under in vitro conditions (2,7,62,63). 
They are also precursors to bile acids. Synthesis and secretion of some oxysterols by 
some tissues can be regarded as an alternative to reverse cholesterol transport by which 
excess sterol is transported to the liver for further catabolism (63). 
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27-OHC is formed in most extrahepatic organs but produced in particularly high 
quantities by macrophages. At high concentrations of the enzyme CYP27A1 this sterol 
may be further oxidized into a steroid acid (3ȕ-hydroxy-5-cholestanoic acid) that can be 
eliminated from the cell even more efficiently than 27-OHC. Our laboratory has 
demonstrated an influx of 27-OHC into the human brain of about 5mg per 24h (64). This 
flux reflects the integrity and function of the BBB. Damage of the BBB thus shows 
higher levels of 27-OHC in the CSF (65, 66). High levels of 27-OHC in CSF may also 
reflect neuronal damage, because of the fact that the metabolizing enzyme CYP7B1 is 
connected to neuronal cells.    
 
Sterol 27-hydroxylase; CYP27A1 
CYP27A1 seems to have a rather stable activity and appears to be mainly regulated by 
substrate availability i.e. cholesterol concentration. Investigations in humans have shown 
no significant difference in transcription levels in the liver at different fluxes of bile acid 
(67). However, the addition of cholesterol to human extrahepatic cells results in a 
significant increase in CYP27A1 activity. This means that the stimulation is mainly due 
to increased substrate availability. The protein CYP27A1 consists of 531 amino acids 
and has a molecular weight of 60 kDa. Two other members of the CYP27 family have 
been identified: CYP27B1 is the important enzyme in connection to bioactivation of 
vitamin D; CYP27C1 has 43% sequence homology to CYP27A1 but the role of this 
form is still under investigation (68). CYP27A1 is an important enzyme involved in the 
acidic pathway for bile acid biosynthesis. As CYP27A1 is present in most cell types, 
extrahepatic 27-hydroxylation represents a quantitatively important extrahepatic pathway 
for bile acid synthesis.  
 
Cholesterol 24-hydroxylase; CYP46A1 
CYP46A1 is expressed in a subset of metabolically active neurons, such as pyramidal 
neurons of the hippocampus, hippocampal and cerebellar neurons, cortical neurons and 
the purkinje cells of the cerebellum (69). These cells display a very high rate of 
cholesterol turnover. The enzyme requires nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH) and oxygen for the conversion of cholesterol to 24S-
OHC in brain microsomes (70). The enzyme consists of ~500 amino acids and has a 
broad substrate specificity. There are a number of endogenous and exogenous 
substrates for this enzyme (71, 72). Cloning of the mouse and human complementary 
DNA (cDNA) revealed unique qualities of the P450s (70). The two different 24-
hydroxylases share less than 35% sequence identity with other members of the P450 
super family. In general human and mouse P450 orthologs are ~70% identical in 
sequence while the CYP46A1 from these two species are 95% identical (73). 
Polyproline motifs like ProAlaProProProProPro-Cys or similar sequences are found at 
the extreme C termini of the mouse and human proteins. This feature is also present in 
the chimpanzee, rhesus, cow, dog, horse, and rat cholesterol 24-hydroxylases but is 
absent in the frog, chicken, zebra fish, and platypus enzymes (74). Other P450s lack 
such features. These motifs are usually binding sites for interacting proteins that are of 
importance for the function of this enzyme (69).  No such interacting partners have yet 
been identified. The structure of the enzyme is organized into 12 Į-helices and four ȕ-
pleated sheets. The heme prosthetic group is positioned between two Į-helices and is 
liganded to cysteine 437 of the protein. An active site with a small volume (~300 Å3) is 
present in which a high-affinity substrate (cholesterol 3-   sulfate) is bound via a 
combination of hydrogen bonding and hydrophobic packing with amino acids from 
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multiple Į-helices (69, 75). Based on     binding studies with the pure enzyme Mast et 
al. (72) defined a number of inhibitors. In   paper II we study the possibility that one of 
these also inhibitors, Voriconazole, has an inhibitory effect on CYP46A1 in vivo. 
 
Investigations on the promoter region of CYP46A1 showed classical features of a gene 
with a housekeeping function (73). The gene has a  TATA-box or CAAT box free 
promoter, multiple transcription sites and a high guanine-cytosine (GC) content of the 
proximal part of the promoter, features often found in genes with house keeping 
function (70, 73). CYP46A1 appears to be insensitive towards a number of regulatory 
factors and experiments with a variety of promoter constructs and hormonal factors did 
not result in significant reporter activity.,oxidative stress, however, caused a significant 
increase in gene reporter activity (73). The GC rich region of the CYP46A1 promoter 
contains a number of putative specificity protein (Sp) binding sites (73) which may be 
of importance in connection with oxidative stress (76, 77). In this connection a recent 
work by Milagre et al. is of interest (78), demonstrating that Sp3 and Sp4 binding is 
required for high levels of CYP46 promoter activity. Little is thus known about the 
transcriptional modulation of this gene by endogenous or exogenous signals. In the 
present work we have studied the possibility that epigenetic mechanisms may be 
important for the regulation of the enzyme. Unlike most P450s that are expressed in 
liver, kidney, and lung, CYP46A1 expression is almost exclusively confined to the 
brain in the mouse and human (69).  In the mouse, small amounts of Cyp46a1 mRNA 
may be detected in the testis and liver, but the mRNA does not appear to be translated 
into protein in the testis, and levels of the mRNA and protein are estimated to be 
approximately 100-fold lower in the liver than in the brain (69). The mouse embryo 
expresses the gene at day 11, with a gradual increase in both mRNA and protein 
expression. In humans the steady state expression level is reached after approximately 1 
year and is maintained during adulthood (69, 73). The expression of the enzyme is thus 
regulated by unknown mechanisms during the first period of life. It has been shown in 
mice that CYP46A1 mRNA levels increase in parallel with the levels of 24S-OHC and 
a decrease of cholesterol synthesis during the first two weeks of life (73).  
Recent reports on CYP46A1 knock out mice indicate that synthesis and turnover of 
cerebral cholesterol via 24-hydroxylation may play an important role for memory and 
learning ability. Kotti et al. reported that mice lacking CYP46A1 have reduced N-
methyl-D-aspartate receptor mediated long-term potentiation in hippocampus and 
memory defects (80). This could be due to the feedback inhibition of HMGCR by 
decreased cholesterol concentration, leading to reduced flux in the mevalonate 
pathway. 
 
Epigenetic regulation 
Our failure to demonstrate a transcriptional regulation of CYP46A1 by the factors 
involved in cholesterol homeostasis in extracerebral tissues, led us to consider the 
possibility of an epigenetic type of regulation (Paper I). This type of regulation 
involves acetylations, methylations, de-acetylations and de-methylations of histones.  
Histone deacetylase inhibitors (HDACi) are a relatively new class of pharmacological 
agents capable of regulating the rate of gene transcription by hyperacetylation of 
histones. There are 5 different classes of inhibitors: 1) hydroxamic acid; 2) short-chain 
fatty acids; 3) synthetic benzamide derivatives; 4) cyclic tetropeptides and 5) 
miscellaneous compounds (81). Valproate and Trichostatin A (TSA) are two often used 
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HDACi. Recent interest in HDACi has grown due to their potential use in anti-cancer 
treatments and the recognition that histone modifications are of importance for 
memory. HDACi’s can induce recovery of tumour suppressor genes, growth arrest, 
differentiation and apoptosis (82).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The effect of histone deacetylase inhibitors Valproate and Trichostatin A on gene 
expression. The action of HDACi’s results in hyperacetylation of histone tails. HDACi’s inhibit 
histone deacetylases allowing activation of histone acetyltransferases. This acetylation adds an 
additional negative charge onto the histone tails that neutralises the positive charge on the 
histones and decreases the interaction between histones and the negative charge on the DNA 
molecule. This causes a relaxing of chromatin structure and is associated with increased gene 
expression levels.    
 
Alzheimers’ disease 
AD was first described by the psychiatrist Alois Alzheimer in Munich in 1906 (83). AD 
is the most common form of dementia, affecting up to 15 million individuals 
worldwide annually. Due to increase in life expectancy, by 2050 it is expected that 
approximately 25% of people living in the Western hemisphere will be over 65 years of 
age, one third of which are likely to develop AD (84). The high prevalence of the 
disease makes investigation on the pathogenesis and potential treatments of AD very 
important. AD is a neurodegenerative disease characterised by the formation of 
amyloid plaques and neurofibrillary tangles. Plaques consist of deposits of 
proteinaceaous material, a major component of which is ȕ-amyloid. The neurofibrillary 
tangles are composed of paired helical filaments of the neuronal phosphoprotein tau.  
 
Cholesterol and oxysterols in Alzheimer’s disease 
Many studies suggest that there is a link between cholesterol metabolism and AD (84). 
A hypercholesterolemic diet was shown to significantly increase ȕ-amyloid load in 
rabbits by increasing both deposit number and size (85). 
Recent studies show that the processing of APP is sensitive to cholesterol levels. 
Cleavage of APP by ȕ-and Ȗ-secretases produces Aȕ. These cleavage events are more 
likely to occur in the high cholesterol environments of lipid raft domains (2). APP is a 
type-I glycoprotein with its amino terminus on the lumenal/extracellular surface and a 
short C-terminal cytoplasmic tail. The major component of amyloid plaques, the Aȕ 
peptide (showed in figure 5), is produced by the ȕ secretase pathway, where APP is 
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first cleaved at the N-terminus of Aȕ (ȕ-cleavage) and then in the transmembrane 
domain (Ȗ-cleavage), either at position 40 or 42. In contrast, APP is more frequently 
cleaved at the Į-position, between amino acids 16 and 17 of the Aȕ region, precluding 
the generation of Aȕ. The APP C-terminal fragments produced after Į and ȕ cleavage 
of  APP are also respectively called C-83 and C-99, based on the number of amino 
acids (86). A study on a transgenic-mouse model for AD demonstrates that high dietary 
cholesterol increases Aȕ-accumulation and accelerates the AD-related pathology (87). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Amyloid precursor protein (APP) is a transmembrane protein that can undergo 
different cleavage pathways which result in either a soluble (P3) nonpathogenic or an insoluble 
pathogenic product (Aȕ40). The activity of the enzyme CYP46 may affect the balance between 
Į- and ȕ- secretase activities as indicated. 
 
Interestingly, polymorphisms in the CYP46A1 gene has been suggested to influence 
both Aȕ peptide load in the brain and the genetic risk for late onset sporadic AD 
(LOAD). A single nucleotide polymorphism in intron 2 of CYP46 gene has been 
identified and reported to be significantly associated with increased risk for LOAD. 
According to the report, the frequency of the CYP46A1 T allele and TT genotype was 
significantly higher in AD patients from Switzerland, Greece, and Italy than in controls 
(88). It has also been reported that the CYP46A1 C allele might act as a risk factor for 
LOAD in Italian patients, meaning that the susceptibility polymorphism might differ in 
different ethnic groups (89). Recently, Kölsch et al. (90) identified two single 
nucleotide polymorphisms in CYP46A1 influencing AD risk and suggested that 
CYP46A1 gene variations might act as risk factors for AD via influence on brain 
cholesterol metabolism. During recent years the research about the relationship 
between polymorphism in CYP46A1 and AD has however given contradictory results 
and the most recent meta-analysis of the available data indicates no effect of the 
CYP46A1 polymorphisms. One possible reason could be the variability between 
different ethnic groups (91). 
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Our group has suggested that an upregulation of CYP46A1, resulting in an increased 
production of 24S-OHC may be neuroprotective and reduce formation of amyloid. One 
reason for this is the effect of 24S-OHC itself on amyloid formation as demonstrated in 
cultured neuroblastoma cells (92). Another reason is that increased consumption of 
cholesterol in the critical neuronal membranes as a consequence of increased activity of 
CYP46A1 would be predicted to reduce amyloid generation (Fig 5).   
 
Levels of 24S-Hydroxycholesterol in AD 
The possibility that altered plasma levels of 24S-OHC and other oxysterols may serve 
as markers of neurodegenerative processes such as AD has been extensively examined 
and assessed (93-97).  
Reduced number of neuronal cells as a consequence of neurodegeneration would be 
expected to reduce the level of 24S-OHC in plasma.  
Levels of 24S-OHC appear however to correlate with the stages of AD, with higher 
levels reported in early stages of the disease. This initial elevation may be due to an 
initial increased conversion of cholesterol to 24S-OHC due to increased substrate 
availability in connection with neurodegeneration and release of the cholesterol (95). 
This effect may be followed by decreased levels of 24S-OHC caused by loss of 
neuronal cells containing the CYP46A1 enzyme (94). Two studies have found 
induction of CYP46A1 in glial cells in the brain of AD patients, which suggests that 
reactive astroglial cells may be involved in turnover of cholesterol in AD brains (98, 
99). The amounts of CYP46A1 in neuronal cells was decreased but was in part 
compensated by an induction of the enzyme in glial cells. The compensatory induction 
of CYP46A1 in astroglial cells may tend to counteract the decrease in plasma levels of 
24S-OHC as a consequence of the neuronal loss. 
It was also shown that the levels of 24S-OHC in CSF are elevated in AD patients 
indicating the possibility that CSF 24S-OHC may serve as a marker for 
neurodegeneration and may be used for monitoring the onset and progression of AD 
(100, 101). This possibility is the subject of paper V. 
 
Fatty acids in the brain 
Western diets are high in saturated fat and in combination with the sedentary lifestyles 
they have contributed to a growing incidence of obesity, hypercholesterolemia, and 
high blood pressure, causing atherosclerosis, coronary artery disease, and diabetes, 
major risk factors of AD (102). Fatty acids serve as both energy substrates and are 
essential for proper neuronal and brain function (102,103). With respect to the latter 
function polyunsaturated fatty acids (PUFA) are integral membrane lipids that serve to 
maintain both the structure and function of neuronal membranes, membranes that are 
associated with proteins and protein complexes. 
The long-chain polyunsaturated fatty acids belong to two key families: omega-3 and 
omega-6, named after the position of the first double bond in the hydrocarbon chain 
counted from the methyl end. Docosahexaenoic acid (DHA) is the most abundant 
omega-3 fatty acid in the mammalian brain, which levels in brain membrane lipids can 
be altered by diet, and age (102, 104). DHA is considered to be an essential PUFA as 
de novo production is not possible in humans. Eicosapentanoic acid (EPA, 20:5n3) and 
Į-linoleic acid (ALA, 18:3n3) can be converted to DHA by some cell types and organ 
systems in the body. There is however a great variability in the degree to which this can 
be accomplished in humans. While ALA can be derived from terrestrial plants and is 
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commonly found in a Western or terrestrial-based diet, DHA and EPA, initially created 
by photosynthetic microalgae, are almost exclusively derived from marine animals. 
Little EPA or ALA is found in the brains of humans, again attesting to the importance 
of DHA in the maintenance of neuronal membrane integrity and the signalling cascades 
related to PUFAs in the brain. According to a current concept, ratios of omega-3 to 
omega-6 PUFAs may be as important as absolute levels of these lipids in the 
homeostasis of CNS inflammation and oxidative stress (105). Very high levels of fatty 
acids and lipids can be found in the neuronal membrane and in the myelin sheath. 
About 50% of the lipids in neuronal membrane are composed of polyunsaturated fatty 
acids, while in the myelin sheath these lipids constitute about 70%.  The integrity of the 
myelin is of utmost importance for the proper functions of axons in the nervous system. 
Breakage or lesions in the myelin can lead to disintegration of many of the nervous 
system functions. Recent studies emphasize the major role of dietary essential fatty 
acids to the normal functions of myelin. Moreover, the essential fatty acids are 
important in the active phase of the myelin synthesis. If essential fatty acids are not 
available in this phase or are metabolically blocked, amyelination, dysmyelination, or 
demyelination may occur (106). High DHA consumption is associated with reduced 
AD risk (102). A general consensus is that saturated fat should be reduced in our diet, 
whereas consumption of n-3 PUFAs should be increased. The recommendations vary 
widely among different countries as well as among nutritionists,  and we still do not 
know the intake of n-3 PUFAs and the ratio of n-6 to n-3 PUFAs that would achieve 
optimum health benefits. The possibility that n-3 PUFAs are important for the activity 
of the CYP46A1 was studied in paper III. 
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Aims of the study 
The following questions were asked: 
x Is there a regulation of CYP46A1 at the epigenetic level? 
x Is the drug Voriconazole also an inhibitor of CYP46A1 in vivo? Does the use of 
this drug cause changes in brain cholesterol homeostasis? 
x Is there a dietary regulation of CYP46A1 by omega3 fatty acids? 
x What are the metabolic consequences of an upregulation of CYP46A1? 
x An interaction between 24S-OHC and APOE has been demonstrated in vitro. Is 
there a correlation between APOE and 24S-OHC in CSF? 
x Can levels of 24S-OHC in CSF be used as a marker for neurodegeneration? 
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MATERIALS AND METHODS 
The following is a summary of materials and methods used.  A more detailed account is 
available in the respective papers. All experiments have been approved by the local 
ethical committee.   
Paper I 
Cell experiment- Neuroblastoma cells were exposed to TSA at a final concentration 
of 0.5 ȝM. After 0, 0.5, 1, 2, 4, 8 and 24 h of incubation the medium was removed 
and the cells were scraped into Trizol and stored. 
Animal Experiment I—Long term effects of Valproate treatment. Six-week-old male 
C57/B6-J mice (n = 5) were injected intraperitoneally with 700 mg/kg Ergenyl 
(valproic acid). Controls (n = 5) received an equal volume of vehicle. Injections were 
continued for five days. On day six the animals were stunned with CO2 and killed by 
cervical dislocation. Organs were removed and stored at -80ÛC. 
Animal Experiment II—Acute effect of TSA treatment. C57/B6-J mice were injected 
intraperitoneally with 0, 2, 5 and 10 mg/kg of TSA. Two hours after injection mice 
were stunned with CO2 and killed by cervical dislocation. Organs were removed and 
stored. 
Animal Experiment III—Long term  effects of TSA treatment. Male C57/B6-J mice 
(n = 5) were injected intraperitoneally with 2 mg/kg TSA. Controls (n = 5) received 
an equal volume of vehicle. Injections were continued for nine days. On day nine the 
mice were stunned with CO2 and killed by cervical dislocation. Organs were collected 
and stored. 
Gene expression analysis. Total RNA was purified from cell or tissue samples using 
Trizol. cDNA was synthesised and steady-state mRNA levels were  estimated using 
either Taqman probes or SYBR green chemistries. Cyclophilin A and hypoxanthine-
guanine phosphoribosyl transferase (HPRT) were used as endogenous controls for 
cell culture and tissues. 
Lipid extraction and analysis. Brain and liver tissue were homogenized according to 
Folch’s method (107, 108). Extracts were dried under argon, redissolved in ethanol 
and stored at í20 °C until required. Sterols were analysed by gas chromatography–
mass spectrometry (GC-MS). 
Statistics. Gene expression data is expressed as mean ± range as described in Livak 
(109). Statistical comparisons were performed using the 2-tailed Students t-test, with 
the exception of the in vivo effects of histone deacetylase inhibitors on CYP46A1 
expression. In accordance with our hypothesis that this gene is derepressed by these 
agents a one-tailed Student’s t-test was used. A P value of less than 0.05 was 
considered significant. 
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Paper II 
Voriconazole (vFEND®) was a generous gift from the department of pharmacology at 
Karolinska University Hospital in Huddinge. C57/B6 J mice were all seven weeks old 
males purchased from Charles River. 
 
Animal experiment I- Acute Effects of Voriconazole - C57/B6 J mice (n = 2) were 
injected intraperitoneally (Ip) with Voriconazole (60mg/kg) and two control mice were 
injected Ip with 1% albumin solution. The mice were sacrificed by cervical dislocation 
after 6 hours. Organs were removed and stored. 
 
Animal experiment II- Acute Effects of Voriconazole- As described above, C57/B6 J 
mice (n = 2) were injected Ip with Voriconazole but with 75mg/kg instead of 60mg/kg. 
The control mice (n = 2) were injected Ip with 1% albumin solution. The mice were 
sacrificed after 6 hours. Organs were removed and stored. 
 
Animal experiment III- Acute Effects of Voriconazole- C57/B6 J mice (n = 5) were 
injected with Voriconazole (60mg/kg) as described previously. Control mice (n = 5) 
were injected Ip with 1% serum albumin. The mice were sacrificed 6 hours later. 
Organs were collected and stored. 
 
Animal experiment IV- Long Term effects of Voriconazole- C57/B6 J mice (n = 6) were 
injected with Voriconazole (60mg/kg). Control mice (n = 6) received 1% serum 
albumin as described above. Injections were continued for 5days. On the fifth day the 
animals were sacrificed and organs and plasma were collected as described above.  
 
Time course study- Effect of Voriconazole over time- C57/B6 J mice (n = 6) were 
injected with Voriconazole (60mg/kg). Control mice (n = 6) received 1% serum 
albumin. The treated animals and their respective controls were sacrificed as described 
above after 0, 2, 4, 6, 12, 24 hours.  Organs and plasma were collected and stored. 
 
Lipid Extraction 
Lipids were extracted from the tissues as described in paper I according to Folch (cf. 
above). 
 
Sterol analysis 
Sterols were determined by isotope dilution–mass spectrometry (110). For 
determination of free cholesterol the samples were hydrolysed and [2H6] cholesterol 
was used as internal standard. [2H3] Lathosterol was used as internal standard for 
determination of lathosterol. The oxysterols, 24S-hydroxycholesterol and 27-
hydroxycholesterol in the brain were analysed by GC-MS) (110). 
 
Gene Expression Analysis- Total RNA was extracted from tissues . 
 
Statistics-Gene expression data is expresses in mean ± range as described in paper I. 
Sterol determinations are presented as mean ± standard error of the mean (SEM). For 
statistical comparisons a two tailed student’s T-test were preformed. 
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Paper III  
Animals and Diets  
Forty two 8-week-old male Golden Syrian hamsters (Harlan Sprague Dawley, Inc., 
Indianapolis, IN) were used in this experiment. After a  initial 1-week adaptation 
period on a standard rodent diet AIN-93M (the diet of the American Institute of 
Nutrition for maintenance of mature rodents). 6 animals were sacrificed after 
overnight fasting (~16 hrs), and the other 36 animals were randomly assigned to three 
groups (n=12) and placed on experimental diets for 6 weeks. All diets contained 
cholesterol in the amount (0.025%) which is non-atherogenic for hamsters and 
equivalent to human intake of <300 mg/day. Palm oil, olive oil, safflower oil, and 
pharmaceutical grade fish oil were the major sources of SFAs, MUFAs, n-6 and n-3 
PUFAs, respectively. Food and fresh water were provided ad libitum. Body weight 
was monitored weekly, and food intake daily at the end of the dark period. While all 
dietary groups had unrestricted access to food and always had some food left before a 
new portion of food was given to them, the total food consumption was reduced by 
8% in group 3 fed the highest fish oil diet. This reduced food consumption led to a 
decreased by ~20% gain in the body weight in this group, however, did not seem to 
affect animal behavior or cause visible signs of malnutrition. After six weeks on 
custom diets, hamsters were deprived from food, and ~16 hrs later sacrificed in a 
chamber containing carbon dioxide. Blood was withdrawn immediately via cardiac 
puncture. Internal organs were excised, rinsed in cold 0.9% NaCl, blotted, cut into 
pieces, weighed, and flash-frozen in liquid nitrogen. All tissues were stored at -80oC. 
The research was conducted in conformity with the Public Health Service Policy on 
Humane Care and Use of Laboratory Animals and approved by the University of 
Texas Medical Branch at Galveston Institutional Animal Care and Use Committee 
(protocol # 0707030). 
Quantification of CYP46A1 protein in the brain 
Total brain protein was separated by SDS-PAGE and transferred to a nitrocellulose 
membrane followed by the incubation with the rabbit polyclonal antibodies against 
human CYP46A1 (a generous gift from Dr. D Russell, UT Southwestern) and sheep 
anti-rabbit immunoglobulins conjugated with horseradish peroxidase. CYP46A1 and 
beta actin (used as a loading control) were detected. Chemiluminescent signals from 
both proteins were recorded and quantified and the CYP46A1/actin ratio calculated. 
Quantification of sterols 
24-Hydroxycholesterol, 27-hydroxycholesterol, lathosterol, cholesterol and 7-
ketocholesterol in the brain were measured by GC-MS. 
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Paper IV (Manuscript) 
Construction of Human CYP46 Overexpressor Transgenic Mice  
Two 1,6-kb fragments (one included an HA-tag sequence) encoding for the human 
CYP46 cDNA was inserted into the EcoR1 restriction site in a pCAGGS expression 
vector (kindly provided by Prof. J Miyazaki). The pCAGGS vector contains the 
chicken ȕ-actin promoter and rabbit ȕ-globin poly(A) signal permitting an ubiquitous 
overexpression of the human CYP46 cDNA in all tissues. The microinjections were 
made by the core facility of Karolinska Institute (Karolinska Center for Transgene 
Technologies).  
Genotyping of Transgenic Mice 
The animals were tail clipped and genomic DNA was isolated  The offspring were 
screened for the presence of transgenes by PCR analyses using specific primers. 
Positive transgenic mice were identified by tail DNA/PCR genotyping. PCR 
amplification was performed using primers specific to the human transgenic CYP46 
sequence. The PCR resulted in a 193-bp fragment for the human cDNA transgene 
sequence.  
Copy number 
A method was established to evaluate the degree of overexpression among the 
positive transgenic mice using genomic tail DNA. Increasing amounts of genomic 
DNA were analysed by RT-PCR. One primer/set detected the human cDNA sequence 
of CYP46A1 whereas the other primer/set detected the mouse genomic Gpbar1 
sequence. To estimate the amount of copies of the hCYP46A1, the slopes obtained by 
the regression of the Ct values and the amount of gDNA loaded in the reaction for the 
amplification of hCYP46A1 were divided by the slopes obtained from the 
amplification of the mGpbar1. 
Back crossing 
The mice with a HA-tag sequence were backcrossed with C57/Bl/6NCrl for 7 
generations and then characterized. The mice without a HA-tag sequence were 
backcrossed for a few generations only before a preliminary characterization.   
Western Blot Analysis 
Microsomes prepared from brains, both transgenic and normal mice were subjected to 
electrophoresis in three different amounts and transferred to nitrocellulose 
membranes. The membranes were incubated for 2 hrs at room temperature in 
blocking buffer followed by incubation overnight in cold room with an anti-CYP46 
antibody (a generous kind gift from Prof. D. Russell, University of Texas 
Southwestern Medical Center, Dallas,TX). As a secondary antibody, Goat-anti-rabbit 
coupled with horseradish peroxidase was used and incubated at room temperature for 
2 hrs. In some experiments a human specific antibody: Rabbit polyclonal to CYP46 
was used with Goat-anti-rabbit as a secondary antibody.  A signal at (around 50 kDa) 
was detected. The results of the signal from each sample in triplicate were calculated 
as a linear value.  
Lipid Extraction and Analysis 
Lipids from brain and liver was extracted and analysed as described above. 
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Paper V and VI 
Paper V- All patients included in the study were referred for cognitive impairment 
and suspected dementia from general practitioners in the greater Stockholm 
catchment area to the Memory Clinic at Karolinska University Hospital in Huddinge, 
Stockholm, during a period of 3 years. They underwent a comprehensive 
investigation including clinical examination, routine blood and CSF laboratory tests, 
electroencephalography (EEG), magnetic resonance imaging   (MRI), and single 
photon emission computed tomography (SPECT). The cognitive evaluations included 
mini-mental state examination (MMSE) as well as comprehensive 
neuropsychological tests. 
The 38 patients studied had a wide variation in the degree of cognitive impairment, 
from MCI to manifest AD with dementia, to reflect a continuum of cognitive 
impairment from mild to severe. The AD group included 18 patients, 10 men and 8 
women, mean age 7 ± 4.2 years (range 69–85), MMSE 23.1 ± 5.4 (range 7–28). 
Alzheimer's disease was diagnosed according to the DSM-IV criteria (111). The MCI 
group included 20 patients, 10 men and 10 women, mean age 59 ± 10 (range 49–86), 
MMSE 28 ± 2.1 (range 22–30). The MCI diagnosis was assessed according to 
previous published criteria (112). All MCI subjects were referred for evaluation of 
cognitive impairment from general practitioners. The majority of the patients had 
memory problems, some of them had additional cognitive impairments. A minority 
had non-memory cognitive problems. Thus, this cohort represented a heterogeneous 
group of patients with several disorders explaining the cognitive impairment. The 
group is probably dominated by very-early Alzheimer's disease subjects but to what 
extent can only be established in a longitudinal follow-up study. 
Paper VI- The patients included in the study were referred to Karolinska University 
Hospital in Huddinge, Stockholm. The MCI and AD groups were referred to the 
Memory Clinic from primary care centres in the catchment area for investigation of 
suspected dementia. These patients were all living independently in the community, 
i.e., they were not in need of formal care or aid from the community. They were 
evaluated according to a standard comprehensive protocol (113) including clinical 
examination, brain imaging  MRI and SPECT, EEG, analyses of blood, urine and 
CSF (T-Tau, P-Tau, and Aȕ42) and a detailed neuropsychological evaluation. 
Dementia and AD were diagnosed according to DSM-IV(55) and NINCDS-ADRDA 
(114) criteria. MCI patients were: (1) not demented; (2) had self and/or informant 
report of cognitive decline and impairment on objective cognitive tasks; (3) had 
preserved basic ADL/minimal impairment in complex instrumental functions (112). 
The control group included patients referred to the Neurology Clinic for headache of 
uncertain cause. They underwent a comprehensive clinical and laboratory evaluation 
which ruled out any signs of organic CNS disease. 
Analysis of CSF - CSF was collected for diagnostic purposes by lumbar puncture. T-
tau was determined using a sandwich enzyme-linked immunosorbent assay (ELISA) 
constructed to measure t-tau (both normal tau and p-tau). p-Tau (P-Thr181) was 
determined using a sandwich ELISA, with monoclonal antibody (MAb) HT7 
(recognizing all forms of tau) used as capturing antibody and biotinylated MAb 
AT270 (specific to P-Thr181 p-tau) used as a detection antibody. Aȕ42 was 
determined using a sandwich ELISA specific for Aȕ42.  
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APOE levels in CSF were assayed by a slight modification of a commercial 
immunoassay for APOE in plasma. In the assay of APOE in CSF, undiluted CSF 
samples were analyzed in contrast to assay of plasma where dilutions 1:20 were used.  
CSF levels of 24- and 27-OHC were assayed by isotope dilution-mass spectrometry a. 
Statistical calculations- Analysis of variance and Student's test were used for group 
comparisons, while the Pearson correlation coefficient was used for correlations. The 
level of significance was set to P = 0.05. 
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RESULTS AND DISCUSSION 
 Paper I  
Is there a regulation of cyp46a1 at the epigenetic level? 
Derepression of CYP46A1 Expression by TSA 
The mechanism(s) underscoring the ectopic expression of CYP46A1 has yet to be 
established. We thus investigated if CYP46A1 expression may be regulated by 
histone acetylation status. Treatment of SH-SY5Y neuroblastoma cells with TSA, led 
to a marked time dependent derepression of CYP46A1 expression which essentially 
restored the expression of CYP46A1 to that of neurons (Fig 6a). This observation was 
replicated in HepG2 hepatoma cells (results not shown). To further validate these 
findings we also performed RT-qPCR on SH-SY5Y cells treated with 0.5 PM TSA 
for 48 hours and observed a highly significant 150-fold increase in CYP46A1 
expression (P < 0.00001) (Fig 6b). For reasons of comparison we also measured the 
expression levels of other genes known to be important for brain sterol homeostasis. 
There was a significant effect on the expression of CYP27A1 that increased about 5 
fold, while the expression of CYP7B1 was decreased to about 10% of the control 
levels (P < 0.0001). 
 
 
 
 
 
 
 
Figure 6. Derepression of cholesterol 24-hydroxylase by histone deacetylase inhibition. A) SH-
SY5Y cells were treated with 0.5PM of TSA for the indicated time periods and gene expression 
was evaluated by reverse transcription-PCR; B) SH-SY5Y cells were treated with 0.5PM of 
TSA for 48 hours and relative gene expression was evaluated by quantitative reverse real-time 
PCR. HPRT was used as internal control. 
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Effects of Valproate Treatment on Cholesterol Homeostasis in mice 
 
Given the potent effects of histone deacetylase inhibition on the mRNA levels of 
CYP46A1 under in vitro conditions, we considered it important to define if this effect 
could be replicated in vivo. Initially we used the anti-epilieptic and anti-anxiolytic drug 
valproic acid (VPA), which is well known to have histone deacetylase inhibitor 
activity. Intraperitoneal injection of a high dose of VPA (700mg/kg) resulted in a 
modest induction in the mRNA expression of Hmgcr and CYP46A1 in the liver, and 
CYP46A1 in the brain. It should be emphasized that the basal expression of CYP46A1 
in the liver was very low. However, treatment with VPA at this level led to the death of 
three of the treated mice, two at day three and one at day four indicating that the 
observed changes in mRNA levels could have been influenced by the general toxic 
effects of VPA. A similar experiment with a lower dose of VPA (350 mg/kg body 
weight) led to a similar pattern of changes of mRNA with a significant increase in 
Hmgcr expression (P < 0.05) while there was a 1.5-fold increase in CYP46A1 (P < 
0.05). There were no matching changes in hepatic or cerebral steady-state sterol levels. 
To exclude the possibilty that the capacity for downstream sterol metabolism (i.e. 7D-
hydroxylation of 24S-OHC) may have been altered by VPA treatment, we measured 
the mRNA levels of Cyp39a1 in both the liver and brain. Surprisingly, we found a two-
fold increase in expression of Cyp39a1 in the brain (P<0.01) and a 50% decrease in 
hepatic expression (P < 0.002) (Fig 7b). 
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Figure 7. Effects of Valproate treatment on hepatic and cerebral gene expression in the mouse. 
Following intraperitoneal injection of low or high doses of Valproate, gene expression in the 
brain and liver was evaluated. A) Dose dependent effects on the expression of Hmgcr and 
CYP46A1. Treatment with Valproate led to modest dose dependent changes in the mRNA 
expression of Hmgcr and CYP46A1 in the liver, and CYP46A1 in the brain. B) Divergent 
regulation of Cyp39a1 expression in brain and liver. Treatment with Valproate lead to a two-
fold increase in expression of Cyp39a1 in the brain (P<0.01), while hepatic levels were reduced 
to approximately half of the control value (P < 0.002) (Fig 7b). 
 
Effects of  TSA Treatment on Cholesterol Homeostasis 
In light of the above mentioned toxic effects of high dose VPA treatment we decided to 
test the potent histone deacetylase inhibitor TSA. We initially studied the dose 
dependent effects of TSA treatment in an acute model. IP injection of TSA to male 
mice at doses from 2 mg/kg to 10 mg/kg body weight resulted in dose dependent 
increases in the expression of brain of CYP46A1 and Cyp39a1. This was recapitulated 
in the liver with increases in hepatic CYP46A1 and Cyp7b1 expression and decreases 
in both Hmgcr and Cyp39a1 levels (Paper I). Intriguingly, the response of female mice 
to the same regimen was markedly different (results not shown).  
  
We then treated animals with 2 mg/kg TSA for nine days. This resulted in a small but 
significant reduction in brain Hmgcr mRNA expression (P < 0.05). No significant 
change was observed in the cerebral expression of CYP46A1, Cyp39a1 or Cyp7b1. The 
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situation in the liver was similar to that observed following VPA treatment, with a 2.5-
fold increase in hepatic CYP46A1 expression. In accordance with our hypothesis that 
inhibition of histone deacetylase increases the mRNA levels of CYP46A1, this was 
significant following a one-tailed T-test (P < 0.05). Again, there were no differences in 
the brain or liver sterol levels.  
 
The overall pattern of changes in the mRNA expression of CYP46A1 was remarkably 
consistent under a variety of different treatment schemes. The evaluation of the results 
are complicated by the pharmacokinetic profile of TSA – the plasma half life of this 
compound in mice is in the order of 7-9 minutes and available data indicates significant 
and rapid hepatic metabolism, potentially to less active compounds (115). The short 
half life may be part of the reason for the differences between the acute and chronic 
TSA mediated regulation of selected genes e.g. Cyp7b1.  
 
An intriguing finding of our investigations on the acute effects of TSA was the finding 
of gender specific responses to effects of the treatment. It has been established that 
hepatic expression of Cyp7b1 is greater in male mice, whereas that of Cyp39a1 is 
greater in females (116). This pattern appears to be potentiated by TSA treatment, at 
least under acute conditions, suggesting that epigenetic mechanisms may be a general 
regulator of sexually dimorphic cytochrome P450 expression. 
 
A surprising finding was the detection of significant levels of Cyp39a1 in the brain. 
This cytochrome P450, which is a 7D-hydroxylase specific for 24S-OHC, was 
originally cloned as a liver specific species (116,). Subsequent investigations have 
identified Cyp39a1 mRNA or protein in brain or the non-pigmented epithelium of the 
retina (117). At the current time, the reason for the diametrically opposite regulation in 
brain and liver is unclear. Expression in the brain may provide a plausible explanation 
for absence of changes in brain 24S-hydroxycholesterol - induction of the 24S-OHC 
7D-hydroxylase within the brain may theoretically lead to intracerebral production of 
7D, 24S-dihydroxycholesterol and mask any increase in 24S-OHC content. Attempts to 
identify the latter steroid in mouse brain has failed thus far, however. 
 
It has previously been shown that epigenetic mechanisms may be involved in the 
regulation of sterol synthesis – Villagra et al. demonstrated that lanosterol synthase is 
repressed by histone deacetylase-3 and presented data that some other genes in the 
cholesterol synthesis pathway were regulated by histone deacetylase inhibition (118). 
The current data supports the contention that epigenetic mechanisms may be of 
importance for the regulation of the transcription of several cytochrome P450s involved 
in metabolism and elimination of cholesterol. 
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Paper II 
Is the drug Voriconazole an inhibitor of cyp46a1 also in vivo? Does the use of this 
drug cause changes in brain cholesterol homeostasis? 
 
Inhibition of cholesterol 24S-hydroxylase activity in vitro 
 In the present study we tested four antifungal azoles that are used systemically as 
therapeutic agents with respect to binding to CYP46A1.We established that 
Voriconazole binds with high affinity to CYP46A1 in vitro and efficiently inhibits 
CYP46A1 -catalyzed cholesterol 24-hydroxylation in the reconstituted system. These 
azoles are interesting because of the fact that they are known to pass the BBB. 
When added to full-length human CYP46A1 Voriconazole caused a Type II spectral 
response with a minimum at 412 nm and a maximum at 431 nm (experiments 
performed in the laboratory of Prof. Pikuleva). The spectral Kd was found to be 0.26 
PM and 0.05 PM when Voriconazole was added in methanol and 50% methanol 
respectively (Paper II ). Under the conditions employed with 2.7 PM cholesterol and 
43 PM Voricoanzole the inhibition of cholesterol hydroxylation was 91%. 
When tested at a cholesterol concentration equal to the Km, the Ki value was found to 
be 11 +3 nM. For reasons of comparison Voriconazole was also added to a preparation 
of full length bovine CYP11A1. Also in this case there was a Type II spectral response 
with a spectral Kd of 6.5 PM (Paper II). When added to full-length human CYP27A1 
and to truncated CYP7A1 under the same conditions, there was a weak spectral 
response only. 
 
Inhibition of cholesterol 24S-hydroxylase in vivo 
 
In a pilot study we exposed mice to different doses of Voriconazole, killed the mice and 
their controls six hours after injection and measured the levels of 24S-OHC in the 
brain. The treatment appeared to reduce the levels of 24S-OHC. The levels were 
slightly lower after injection with 60 mg/kg body weight than after injection with 75 
mg/kg boy weight (results not shown). In a subsequent experiment we treated 5 mice 
with Voriconazole, 60 mg/kg body weight as above and killed the animals and their 
controls after 2 hours. The levels of 24S-OHC were reduced by 20% but this effect was 
not statistically significant (p>0.05, Student´s t-test). There was no significant effect on 
levels of lathosterol or total cholesterol in the brain (results not shown).  
 
 The result of an experiment where 6 mice were treated with Voriconazole, 60 mg/kg 
body weight, once daily for 5 days, indicate that there was a significant reduction in the 
levels of 24S-OHC, by about 20 %  (Fig. 8 ). There was no effect on levels of 
cholesterol or 27-OHC (Paper II ). The ratio between lathosterol and cholesterol in the 
brain was significantly reduced, however, indicating a reduced cholesterol synthesis 
(p<0.05).   
 
Since most of the 24S-OHC present in the circulation originates from the brain, a 
reduction of brain synthesis is likely to lead to a reduction of plasma 24S-OHC, unless 
Voriconazole has an effect on the metabolism in the liver. A pool of plasma from the 
Voriconazole-treated mice had a concentration of 24S-OHC of 13 ng/mL. A pool of 
plasma from the control mice had a concentration of 24S-OHC of 19 ng/mL. Thus 
Voriconazole appeared to suppress the plasma levels by about 30%. It should be 
pointed out that the level of the 27-OHC was not significantly affected by the 
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Voriconazole treatment. The levels of this oxysterol was found to be 46 ng/mL and 52 
ng/mL in the Voriconazole treated mice and in the controls, respectively.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. 24S-OHC measured in mice brain after daily injection of Voriconazole. Values are 
expressed mean ± SEM. * = Statistical significant at (P = 0,003) as compared to control. 
 
 
Effects of Voriconazole on the levels of cholesterol precursors upstream of lathosterol 
 
The reduced levels of lathosterol in the Voriconazole-treated mice suggest a reduced 
cholesterol synthesis. Part of this reduction could be due to the inhibition of cyp51, the 
enzyme responsible for demethylation of lanosterol, an upstream precursor of 
lathosterol. In accordance with this, we found that the brain levels of lanosterol 
increased from 6+2 ng/mg tissue in the controls to 27+10 ng/mg tissue in the 
Voriconazole-treated mice (p<0.001). The levels of dehydrolanosterol were 0.14+0.05 
ng/mg tissue and 2.0+0.7 ng/mg tissue, respectively. The levels of the lanosterol 
precursor squalene were 2.2+0.8 ng/mg tissue in the controls and 1.7+0.6 ng/mg tissue 
in the Voriconazole-treated mice (p=0.05). The latter is consistent with a reduction of 
cholesterol synthesis also at a step prior to lanosterol demethylation.   
 
Effects of Voriconazole on mRNA levels of genes involved in cholesterol homeostasis 
  
Voriconazole had no significant effect on expression of CYP46A1 mRNA or Hmgcs 
(Paper II). There was a significant suppressive effect on Hmgcr mRNA levels, 
however (Paper II). 
 
Brain levels of Voriconazole 
 
The level of Voriconazole in the brains of mice (n=5)  after 5 daily intraperitoneal 
injections (60 mg/kg body weight) was 43 + 8 Pg/g wet weight corresponding to 123 
PM. Kinetics of brain levels of Voriconazole after a single injection (60 mg/kg) is 
shown in Fig. 9. 
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Figure 9. Kinetics of brain levels of Voriconazole in mice after a single intraperitoneal 
injection (60 mg/kg body weight). 
 
 
As would have been expected from the structure of the binding site of CYP46A1, 
Voriconazole was found to be an efficient inhibitor of cholesterol 24S-hydroxylase 
activity in vitro.  
In accordance with this, and in accordance with the fact that Voriconazole is known to 
pass the BBB, a statistically significant decrease in 24S-OHC levels could be 
demonstrated in the brains of mice injected intraperitoneally with Voriconazole for 5 
days. 
 
In theory, there are two possible explanations for the reduced levels of 24S-OHC in the 
brains of the treated animals. The first explanation is a direct inhibition of the enzyme 
by Voriconazole. The very high levels of Voriconazole measured in the brain in 
relation to Ki are in accord with this. The second possibility is related to the fact that 
Voriconazole is an inhibitor of cholesterol synthesis. It has been shown that 
Voriconazole exerts its antifungal effect through inhibition of the cytochrome P-450 
enzyme 14 alpha sterol demethylase, CYP51, an enzyme responsible for the 
demethylation of lanosterol in the ergosterol biosynthesis pathway (119). Theoretically 
a reduced synthesis of brain cholesterol may eventually lead to reduced substrate 
availability for the CYP46A1 enzyme with reduced production of 24S-
hydroxycholesterol.  
 
The reduced levelsof lathosterol in relation to cholesterol indicates that brain 
cholesterol synthesis was reduced in the Voriconazole treated mice. This is consistent 
with both the above mechanisms. The fact that the Voriconazole treatment had no 
significant effect on the pool of cholesterol in the brain, does not favour the hypothesis 
that reduced substrate availability is of importance for the reduced production of 24S-
hydroxycholesterol. However, the cholesterol content in some specific brain cholesterol 
pools may have been influenced. Our studies on the whole brain would not be able to 
resolve this issue.   
A primary effect of Voriconazole on CYP46A1 can be expected to lead to reduced 
consumption of brain cholesterol and thus a reduced need for de novo synthesis. The 
finding that the Voriconazol treatment had a suppressive effect on the expression of 
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Hmgcr mRNA is consistent with this explanation. In this connection it is of interest that 
a complete gene knock-out of CYP46A1 in a mouse model is associated with a 
reduction of cholesterol synthesis by about 40% (120). 
 
Treatment with Voriconazole represents a less drastic experimental model for inhibition 
of the enzyme than the knock-out model. Voriconazole may thus be used for detailed 
studies on the relation between CYP46A1 activity and cholesterol homeostasis. In such 
studies it is necessary to define the degree of inhibition of the enzyme by measurement 
of the product 24S-OHC in the brain.  
 
One of the most important side-effects of Voriconazole is visual disturbances. Since the 
neuronal part of the retina contains even higher concentrations of CYP46A1 than the 
brain (121), the possibility may be considered that the visual disturbances in connection 
with Voriconazole treatment are related to an interaction between the drug and retinal 
CYP46A1. If this is the case, visual disturbances would be expected in CYP46A1 gene 
knockout mice. In accordance with this contention, abnormalities in the 
electroretinography (ERG) signals have recently been demonstrated in such mice 
(D.Russell, personal communication). Further work on a possible relation between 
vision and cholesterol 24S-hydroxylase is in progress. 
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Paper III 
Is there a dietary regulation of cyp46a1 by omega-3 fatty acids? 
Choice of animal model and diet 
In this study we chose hamsters since they represent a better animal model for the 
evaluation of the effect of dietary cholesterol and n-3 PUFAs than mice and rats. Also, 
unlike previous animal studies, in which n-3 PUFAs were added to the standard rodent 
chow (122-125), we used “human-like” diets. 
 
Serum lipids 
 
The baseline levels of serum lipids were determined prior to testing the effect of diets. 
Measurements were carried out after a 1-week adaptation period during which the 
animals were fed regular rodent diet AIN-93M. Mean T-C (103 mg/dL), LDL-C 
(61mg/dL), HDL-C (48 mg/dL), and TG (175 mg/dL) were at or around the levels 
suggested as desirable in humans by the American Heart Association (200 mg/dL T-
C, 100 mg/dL LDL-C, !40mg/dL HDL-C, and 150 mg/dL TG). Switching to the 
“human”-like diets 1-3 led to an increase in T-C, HDL-C and TG and a change in the 
LDL-C to HDL-C ratio. This result is consistent with the previous findings by others 
showing that unlike rats and mice, which are highly resistant to the effects of dietary 
cholesterol, hamsters are moderately responsive, and thus represent a better model for 
nutritional studies.  
 
The AIN-93M diet was cholesterol-free and only 9% of calories were from fat, whereas 
diets 1-3 contained 0.025% cholesterol and fat provided 34% of calories. Changes in 
the levels of serum lipids were also observed between the diets. Increased intake of the 
fish oil led to a decrease in the mean levels of LDL-C, HDL-C, and TG in diets 2 and 3 
but only in the highest fish oil group (diet 3) did this decrease reached to a statistical 
significance.  
 
Similar to humans, hamsters in our study had a decrease in TG levels upon increased 
intake of n-3 PUFAs; this decrease, however, did not reach a statistical significance. 
The effect on LDL-C and HDL-C was the opposite to that seen in many, but not all, 
human trials; both lipoproteins were significantly lower in hamsters on diet 3 
containing the highest amount of n-3 PUFAs but the LDL-C/HDL-C ratio did not seem 
to change in the three test groups. 
 
Expression of genes for Cyp7a1, Cyp27a1, and CYP46A1 
 
Cyp7A1 mRNA levels, showed a significant,( ~ 17- to 44-fold), intergroup variability, 
Cyp27a1 a moderate, (4-6-fold), intergroup variability, and CYP46A1 a low, only (2-3-
fold), intergroup variability. Because of this high variability, a decrease in Cyp7a1 in 
groups 2 and 3 was not statistically significant. Cyp27a1 and CYP46A1, however, did 
show a statistically significant increase in group 3 in the liver and brain, respectively. 
The high intergroup variability of Cyp7a1, was present at all levels; mRNA, protein 
and enzyme activity. This result is consistent with the previous findings in humans 
demonstrating that CYP7A1 activity varied markedly, over a 5-10- fold range in 
healthy individuals (126, 127-129) It is likely that it is effects on Cyp7a1 transcription 
that determine different mRNA levels and consequently enzyme activity. In hamsters 
and humans, the gene transcription is not sensitive to cholesterol but is suppressed by 
bile acids (130-134). Transcription factors that negatively regulate Cyp7a1 (the 
farnesoid X receptor, fibroblast growth factors 4 and 15 and the protein ȕ-Klotho (135) 
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are responsive to different stimuli, and this sensitivity to different stimuli may explain 
interindividual variability in the human gene expression as well as our data. Diurnal 
rhythm is also of importance for the activity of Cyp7a1 (136,137). Despite the carefully 
controlled conditions in our study, hamsters still had a marked intergroup variability 
suggesting factors other than age, sex, health status and diet to affect Cyp7a1 
transcription. One of such factors could be starvation or individual differences in the 
time of the last food intake. Both of these factors were reported to affect the Cyp7a1 
mRNA levels (136). Another factor could be genetic differences. 
 
Since CYP27A1 and CYP46A1 are also expressed in the retina (121) we measured 
Cyp27a1 and CYP46A1 levels in the eyeball as well. In these experiments we 
combined three eyeballs, each from a different animal, to obtain one mRNA sample, 
and, thus, had four mRNA samples per group. No differences in abundance of Cyp27a1 
and CYP46A1 in the eyeball were found between the three dietary groups. 
 
Levels of sterol markers for cholesterol synthesis and degradation in the brain 
Of the three sterols measured in the brain, lathosterol, 24S-OHC, and cholesterol, the 
former showed the highest intergroup variability (up to 6.7-fold), 24S-OHC varied up 
to 2 -fold and cholesterol only up to 1.5-fold. Increased fish oil content in diet 3 
appeared to have a slight stimulatory effect on brain levels of 24S-OHC, 27-OHC and 
lathosterol. All these effects were however not significant from a statistical point of 
view.   
Cyp46a1 protein expression in the brain was assessed by comparing the signals from 
Cyp46a1 and actin on Western blots. The Cyp46a1/actin ratio was slightly increased 
in diet 3 but this increase was not statistically significant and was not translated into 
increased serum 24S-OHC levels. Thus, diet 3 had an effect on the CYP46A1 mRNA 
levels in the brain and a trend to increased cerebral cholesterol turnover, yet changes 
in the levels of either Cyp46a1 protein or sterol markers were not significant. 
Cyp27a1 is also expressed in the brain (138, 139), and thus we determined brain 
levels of 27-OHC. In both dietary groups they were more than 170-times lower than 
those of 24S-OHC. Thus, similar to humans and mice 24S-OHC also appears to be 
the major route for enzymatic cholesterol elimination from the brain in hamsters. The 
mean levels and the 27-OHC to cholesterol ratio were slightly higher in group 3 than 
in group 1. The intergroup variability in 27-OHC in the brain was up to 2-fold (not 
shown). 
Increased n-3 PUFAs consumption was found to be positively associated with 
increased oxidative stress in several studies (reviewed in 141). Therefore, we 
measured 7-ketocholesterol, a toxic oxysterol, formed non-enzymatically from 
cholesterol. There was only a slight increase in this oxysterol level in group 3. 
In our study we detected a clear effect of n-3 PUFAs on the Cyp46a1 mRNA levels in 
the brain of hamsters in group 3, and this effect is of interest in relation to a previous 
failure to demonstrate enzyme regulation at the transcriptional level by a number of 
hormonal and dietary factors (73).  The protein and 24S-OHC levels in group 3, 
however, were not significantly increased, and serum 24S-OHC levels were 
unchanged. It is possible that there is a time lag between the mRNA and protein 
synthesis and consequently the production of 24S-OHC. There was a tendency to 
increased cholesterol synthesis but this effect was not statistically significant in group 
3.  
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Studies in mice indicate that cholesterol biosynthesis and elimination are tightly 
coordinated in the brain (140). Mice lacking Cyp46a1 have decreased cholesterol 
elimination from the brain and a compensatory decrease in cholesterol biosynthesis 
(80). The steady state cerebral cholesterol levels in Cyp46a1 knockout mice remain 
the same as in wild type animals but cholesterol turnover is decreased leading to 
deficiencies in memory and learning (80). The consequences of the increased 
cholesterol elimination from the brain were investigated in a recent gene therapy 
study (78). Transgenic mice representing a model of AD were transfected with 
CYP46A1 cDNA in hippocampus and cortex using an adeno associated virus 
approach (143). The treated animals had increased levels of 24S-OHC in the brain but 
unchanged cholesterol levels suggesting increased cerebral cholesterol biosynthesis 
and turnover. These animals showed improved cognitive performance and also had a 
reduced amyloid plaque formation (78). Thus, although we could not demonstrate a 
statistical increase in the cerebral cholesterol turnover in hamsters on diet 3, the 
observed changes are in the direction expected for increased Cyp46a1 mRNA level 
and consistent with the results of many studies indicating that fish consumption or 
intake of n-3 PUFAs beneficial effects on brain function (reviewed in (144)). It 
should be noted that our data does not exclude a possible difference at the ± 10-20% 
level. 
In summary, our nutritional studies in hamsters indicate that Cyp7a1 gene 
transcription contributes to significant interindividual variations in CYP7A1 protein 
levels and enzyme activity and the latter could underlie the different effect of n-3 
PUFAs on serum cholesterol and inconsistent results of human trials. The results are 
consistent with the possibility that increased dietary intake of n-3 PUFAs may lead to 
increased activity of Cyp46a1 and a stimulation of cholesterol turnover in the brain. 
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Paper IV (Manuscript) 
What are the metabolic consequences of an upregulation of cyp46a1? 
 
Characterization of CYP46A1 overexpressing mice 
 
The transgenic mice behaved normally and there was no difference in weight, 
female/male ratio or reproduction between these mice and their non-transgenic 
littermates. No abnormalities were observed in the brain, liver or adrenals. Significant 
levels of mRNA corresponding to human CYP46A1 were detected in brain, liver, 
ovary, testes, eye, kidney and lung. CYP46A1 protein could only be detected in brain, 
testis and the eye. However CYP46A1 protein levels in eye and testis of the 
overexpressed animals appeared to be less than 10% of those in the brain.   
The levels of 24S-OHC were significantly increased in the testis, eye and in the brain 
of the overexpressed mice as compared to those of the wildtype.  The levels of 24S-
OHC in testis and eye were however less than 3% of those in brain. The plasma levels 
of 24S-OHC were increased about 4.5-fold in overexpressed female mice as 
compared to wildtype females. The corresponding figure for male mice was about 
6.5-fold. The fecal excretion of free 24S-OHC was increased more than 20-fold in 
both overexpressed males and females. Immunochemical analysis was made on brain 
of overexpressed and control mice, using antibodies reacting with both murine 
CYP46A1 and human CYP46A1. Similar staining was obtained in the neuronal cells 
of the cortex, cerebellum and hippocampus.  The pattern was identical in the 
transgenic and the wildtype mice with a tendency to stronger staining in the 
transgenic mice. In both cases expression was only observed in the neuronal cells, 
with no significant expression in the glial cells. 
 
 
 
Fig 10. Immunohistochemical analysis of cerebellum (purkinje cells) from control and 
overexpressed mice. The primary antibody used was active towards both mouse and human 
CYP46A1. The right panel shows immunohistochemical analysis of the same region of the 
brain of an overexpressing mouse using antibodies directed towards the HA tag.  For 
experimental details and the picture in colour see paper IV. 
 
Western blotting of electrophoretically separated microsomal brain protein from 
overexpressing and control mice using antibodies active towards both human and 
murine CYP46A1 showed a 2-4 fold increase of CYP46A1 protein as a consequence 
of the overexpression (Fig 11).  
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Fig 11. Western Blott analysis of CYP46A1 in transgenic mice compared to wildtype mouse.  
The brain levels of 24S-OHC were increased almost two-fold both in the male and in 
the female overexpressing mice. There was a high correlation between the levels of 
24S-OHC in the brain and in the circulation. High correlations were also observed 
between mRNA levels of human CYP46A1 and levels of 24S-hydroxycholesterol in 
the brain and in plasma. 
Overexpression of CYP46A1 would be expected to consume cholesterol and result in 
a compensatory increase in cholesterol synthesis. In accordance with this the brain 
levels of a number of cholesterol precursors: 7-dehydrocholesterol, lathosterol, 
lanosterol, dihydrolanosterol, and FF-mas were all increased in the overexpressed 
mice. The levels of T-mas was slightly lower in the brain of the overexpressed mice. 
The levels of desmosterol in the brain of the overexpressed mice were not 
significantly higher than those of the controls. The levels of cholesterol were not 
significantly changes in the brain of the overexpressing mice.  
 
The mRNA level of Hmgcr was slightly increased whereas Hmgcs mRNA in the 
brain was slightly decreased. The mRNA level of Cyp27a1 was significantly 
decreased. The mRNA levels of Srebp1c, Srebp2, Abca1, Cyp7b1, Cyp39a1 and Fas 
were unaffected by the overexpression of CYP46A1. There was no gender difference 
between males and females. LXR target genes were also measured in the liver 
(Cyp7a1, Cyp7b1, Srebp1c, Fas, Abca1, Abcg5, Abcg8).  LXR-activation would be 
expected to increase expression of all the above genes, with the exception of Cyp7b1 
that would be expected to decrease (144). There were marked gender differences in 
the expression of some of these genes. There was a tendency to a decrease in the 
expression of Cyp7b1 (not statistically significant) in the liver of females whereas it 
was significantly increased in males. Instead of an expected increase there was a 
significant decrease in the expression of the LXR target genes Srebp1, Cyp7a1, 
Abcg5, and Fas in the liver of the male CYP46A1 overexpressing mice. A similar 
effect was not seen in the liver of the female CYP46A1 overexpressing mice. 
 
In addition to 24S-OHC, 27-OHC is a major oxysterol in the circulation. Surprisingly, 
the level of this oxysterol was significantly increased both in the brain and in plasma 
of the overexpresed mice. The mRNA level of Cyp27a1, the enzyme responsible for 
formation of 27-OHC, was decreased rather than increased in the brain.  
A possible mechanism behind the increased levels of 27-OHC in the overexpressed 
mice could be a direct inhibition of the oxysterol 7D-hydroxylase by 24S-OHC. In 
order to study this possibility we incubated pig liver microsomes containing Cyp7b1 
activity together with mixtures of 27-OHC and 24S-OHC. When incubating liver 
microsomes with 27-OHC at a saturating concentration together with a 4-fold excess 
of 24S-OHC, the addition of 24S-OHC caused an inhibition by more than 50% of the 
rate of 7D-hydroxylation of 27-OHC. Similar degree of inhibition was also obtained 
at lower substrate concentration. According to a Lineweaver–Burk plot the inhibition 
appeared to be of competitive nature.  
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The use of a ubiquitous expression vector caused expression of human CYP46A1 
mRNA in several different organs with the highest expression in the brain, lung and 
testes. The expression caused a 4-6 fold increase in the level of 24S-OHC in plasma 
and a more than 20-fold increase in the excretion of this oxysterol in faeces. In view 
of the many different possible metabolic pathways for 24S-OHC: sulfatation, 
glucuronidation, omega-oxidation and conversion into bile acids (145), the increase in 
fecal excretion of the free steroid may be  higher than the true increase in over-all 
production of 24S-OHC.  On the other hand it is possible that the relatively moderate 
increase of 24S-OHC in the brain does not adequately reflect the total production and 
flux of 24S-OHC. It is important to emphasize that it may be the rate of the flux of 
the oxysterols rather than their absolute concentration that may be of importance for 
their biological effects. The relatively low levels of 24S-OHC may be due to an 
increased metabolism. Attempts to quantitate the major primary metabolite of 24S-
OHC, 7Į, 24-dihydroxycholesterol, failed, however. mRNA corresponding to the 
oxysterol 7Į-hydroxylase Cyp39a1 were not increased as a consequence of the 
overexpression of CYP46A1. 
 
 Except for the brain, testis and the eye, the levels of CYP46A1 protein were low or 
undetectable in the different tissues tested, both in wildtype and overexpressed mice. 
This was the case also with the levels of 24S-OHC.  Interestingly, next to the brain, 
the highest levels of 24S-OHC were observed in testis and eye, possibly in part due to 
the presence of a blood-testis barrier and a blood-retina barrier. We have previously 
shown that the blood-testis barrier has a preventive effect on the flux of lipoprotein-
bound cholesterol from the circulation into testis (147).  
 
Under normal conditions CYP46A1 is located almost exclusively to the brain in 
mammals, and most or all 24S-OHC originates from this organ. We have shown, 
however, that part of the 24S-OHC present in the circulation of mice may originate 
from other sources than the brain (147). Since there are significant levels of 24S-OHC 
in the circulation of mice homozygous for an induced null allele in the CYP46A1 
gene (120), there must be small amounts of an unidentified enzyme in this species 
capable to introduce a hydroxyl group in the 24-position of cholesterol. How much of 
the increase in circulating levels of 24S-OHC that originates from the brain in the 
present mouse model can not be determined with certainty. In view of the very low 
levels of CYP46A1 protein in any other organs than the brain, it seems likely that 
most of the 24S-OHC in the circulation originates from the brain.  
 
A more detailed investigation with respect to cellular location of the enzyme was 
made only in the brain. The immunohistochemical analysis revealed that the 
expression of the human CYP46A1 transgene was similar to that of the endogenous 
murine CYP46A1, and only neuronal cells were found to contain the expressed 
protein.   
 
The overexpression of CYP46A1 would be expected to lead to a local consumption of 
cholesterol in the cells expressing CYP46A1 with a compensatory increase of 
cholesterol synthesis. In accordance with this, we found significantly increased levels 
of lathosterol and other cholesterol precursors in the brain of the overexpressed mice. 
There was a slight increase in the levels of mRNA corresponding to the rate-limiting 
enzyme in cholesterol synthesis, Hmgcr. A slight but significant effect on Hmgcr 
mRNA level was observed in hippocampus and cortex also in the study by Hurdy et 
al. (143). The total brain cholesterol levels were not significantly affected by the 
overexpression of CYP46A1 in the present work. It should be pointed out that it was 
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the total cholesterol that was measured, including both myelin cholesterol and 
cholesterol in neuronal and glial cells. In the study by Hurdy et al. (143), global 
cholesterol in hippocampus and cortex was unaffected by the overexpression.  
 
In view of the increased levels of 24S-OHC in the circulation and tissues of the 
overexpressed mice, a general activation of LXR and LXR-targeted genes would be 
expected. There was however no significant activation of such genes, neither in the 
brain, nor in the liver. It can be concluded that 24S-hydroxycholesterol is less 
important as a general regulator of LXR-targeted genes. An LXR agonist has been 
shown to have a beneficial effect on neurodegeneration (148), and in view of the 
efficient binding of 24S-OHC to LXR it is tempting to suggest that this oxysterol 
could act by the same mechanism. The present work does not, however, suggest that 
an increase in the expression of 24S-OHC could have a beneficial effect on 
neurodegeneration by activating LXR. A similar conclusion was drawn from the 
results obtained with the mouse model used by Hudry et al. (143). 
 
A surprising finding in the present study was that overexpression of CYP46A1 
increased the levels of 27-OHC in brain and in circulation. We have shown that most 
of the 27-OHC present in the brain of humans originates from the circulation (149), 
and it is likely that this is the case also in mice. The increased levels of 27-OHC were 
not caused by increased expression of the enzyme producing this oxysterol, since 
Cyp27a1 mRNA levels were not increased by the overexpression of CYP46A1, 
neither in the liver, nor in the brain. Another theoretical possibility could be an effect 
on the enzyme responsible for metabolism of 27-OHC Cyp7b1. The expression of 
this enzyme is reduced by LXR-activation (145, 150). The mRNA levels 
corresponding to Cyp7b1 were however not affected by the overexpression of 
CYP46A1 in the brain, and in the liver different effects were obtained in males and 
females. Cyp7b1 is not active towards 24S-OHC, but it was shown that 24S-OHC can 
function as a competitive inhibitor of Cyp7b1 at concentrations similar to those in the 
circulation. We suggest that the increased levels of 24S-OHC may have a direct 
inhibitory effect on Cyp7b1 activity resulting in increased levels of 27-OHC in the 
circulation. This is of interest in relation to the previously unexplained findings of a 
close correlation between levels of 24S-OHC and 27-OHC in CSF of humans under 
different conditions (149, 100). In addition to an effect of 24S-OHC on the activity of 
Cyp7b1 it seems likely that this oxysterol could compete with 27-OHC for other 
excreteory pathways such as glucuronidation, sulfatation or conversion into bile 
acids.  
 
It is concluded that our mouse model with overexpressed human CYP46A1 is 
possible to use for studies on a possible protective effect of its activity on 
neurodegeneration and amyloid accumulation in the brain. Work on this is in 
progress. 
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Paper V 
Is there a correlation between APOE and 24S-OHC in cerebrospinal fluid? 
In control patients there was a significant correlation between the APOE levels and 
cholesterol but no significant correlation with 24S-OHC or 27-OHC in CSF (Fig. 
12A). The APOE levels were not correlated to AlbuminCSF/Albuminplasma ratio (QAlb) 
or CSF albumin. Age was not significantly correlated with 24S-OHC, ApoE, CSF 
Albumin, Cholesterol or 27-OHC. In accordance with the previous finding that the 
levels of 27-OHC in CSF are dependent upon the function of the BBB. There was a 
correlation between 27-OHC and QAlb (paper V). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
Figure. 12. Relation between APOE and 24S-OHC in cerebrospinal fluid from controls (panel 
A)(r = 0.1, p = 0.53), AD patients (panel B) (r = 0.66, p = 0.004) and MCI patients (panel C) 
(r = 0.75, p < 0.001).  
 
In AD-patients the APOE levels were not significantly correlated to cholesterol but 
there was a highly significant correlation to levels of 24S-OHC (Fig.12 B). There was 
no significant correlation to levels of 27-OHC. In similarity with the situation in 
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control patients there was no significant correlation between APOE levels, QAlb or 
CSF albumin. Also in this case the age was not correlated with any of the CSF 
variables studied. 
In MCI patients the APOE levels were not significantly correlated to cholesterol but 
there was a highly significant correlation to levels of 24S-OHC (Fig. 12 C). There 
was no significant correlation to 27-OHC, Albumin or QAlb (r = 0,07, p =0,6 ns). 
Age was not correlated with any of the CSF variables studied. 
We compared APOE levels in CSF with other markers for neurodegeneration such as 
Tau levels in CSF from AD and MCI patients. In the AD patients APOE was found to 
be significantly correlated with Tau and P-Tau proteins but not with the Aȕ1–42. In the 
case of MCI patients the APOE levels were not significantly correlated with Tau and 
P-Tau, but significantly with Aȕ1–42. 
Next we compared the controls with MCI and AD in order to evaluate the 
significance of the detected differences. The AD patients were significantly older than 
the controls and the MCI patients and the latter group was slightly but significantly 
older than controls. With respect to the APOE levels, these were significantly higher 
in the AD and MCI patients than in the controls. The levels of 24S-OHC and 27-OHC 
were significantly higher in AD and MCI patients compared to controls, as reported 
in paper VI. There was no significant difference between the three groups with 
respect to the levels of cholesterol, CSF albumin or QAlb. 
Due to the significant age difference we evaluated the differences observed after age-
correction, even if there was no significant correlation with age for any of the 
variables. After correction for age the levels of 24S-OHC were still significantly 
higher in MCI and AD patients compared to controls. The situation was the same 
with APOE and 27-OHC. It is evident that age is not a significant confounding 
variable in our study. 
The levels of Tau, P-Tau (p = 0.016) and Aȕ1–42 in AD patients were significantly 
higher than in MCI patients. These three CSF markers were not significantly 
correlated to age, QAlb or CSF Albumin. Correction for age did not affect the 
observed differences between groups. 
The highly significant correlation between levels of APOE and 24S-OHC found in 
patients with AD and patients with MCI is in accordance with the in vitro 
demonstration that 24S-OHC has a direct effect on APOE secretion from astrocytes 
(18). A similar strong correlation was not observed in healthy control subjects. A 
possible explanation could be that the coupling between 24S-OHC and APOE 
secretion is most important under conditions with increased levels of 24S-OHC in 
CSF. We and another group found that the levels of 24S-OHC in CSF are increased 
under conditions of neurodegeneration (100, 101), presumably reflecting populations 
of dying neuronal cells. Under these specific conditions the 24S-OHC-mediated 
increase in secretion of APOE may be more important than under normal conditions. 
APOE is a cholesterol-transporting lipoprotein, but we did not find a significant 
correlation between APOE and cholesterol in CSF from patients with 
neurodegeneration. However, a low but significant such correlation was observed in 
the control subjects. 
Under in vitro conditions cholesterol increases cleavage of APP via the 
amyloidogenic pathway, whereas 24S-OHC has been reported to have an opposite 
effect (151, 152). If the neurodegenerative process results in increased levels of free 
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cholesterol, 24S-OHC may have a role both as a suppressor of amyloidogenesis and 
as a stimulator of APOE-mediated removal of cholesterol. It appears that our results 
are consistent with the possibility that 24S-OHC-mediated secretion of APOE results 
in an overcapacity for transport of sterols from CNS under conditions of 
neurodegeneration but not under normal conditions. 
For reasons of comparison, we also included measurements of 27-OHC in our study. 
Most of this oxysterol present in CSF appears to originate from extracerebral sources 
(149). The lack of correlation between 27-OHC and APOE in the two groups of 
patients and in the controls is in accordance with this. 
It is noteworthy that APOE was not correlated to 27-OHC, albumin or Qalb, markers 
of the BBB functionality. It may be concluded that the increased levels of APOE in 
the CSF of AD and MCI patients can not be simply addressed to a dysfunction of the 
BBB. 
As described above the transcription of CYP46A1 has been found to be resistant to 
most regulatory factors tested, and availability of substrate cholesterol may be the 
most important factor under normal conditions (73). Oxidative stress was one of the 
few factors capable to up-regulate the gene at a transcriptional level (73). Since 
oxidative stress occurs in CNS of patients with AD (156), it is possible that this may 
contribute to increased formation of 24S-OHC and increased flux of APOE from the 
astrocytes. 
Here we found that the CSF levels of APOE were significantly increased in AD and 
MCI patients. Previous measurements of APOE in CSF from patients with 
neurodegeneration have given contradictory results and increased (153-155), 
decreased (157-160) or unchanged levels have been reported (161). The different 
results observed by the different authors may be due to methodological differences 
and /or the characteristics of the control population used in each study. 
In paper VI we showed that 24S-OHC is a promising marker for both early and 
advanced neurodegeneration (100, and Paper VI). The high correlation between 24S-
OHC and APOE in CSF from such patients is consistent with the possibility that also 
APOE levels may be used diagnostically. At present, the level of T-Tau protein is 
generally used as a diagnostic marker for neurodegeneration (167) and it is 
demonstrated here that also the levels of T-Tau protein correlated to the APOE levels 
in our patients.  
 
 
 
. 
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Paper VI 
Can levels of 24S-OHC in CSF be used as a marker for neurodegeneration? 
We tested the possibility that 24S-OHC in CSF may be used as a marker for 
neurodegeneration. The levels of 24S-OHC in CSF were found to be significantly 
positively correlated with t-tau as well as p-tau, considering all the patients together 
(Fig. 13 A and B). Similar correlations were found between 24S-OHC and t-tau and 
p-tau both in the AD and MCI cases. There was no significant correlation between 
CSF levels of 27-OHC and t-tau or p-tau, respectively. 
 
Figure 13. Correlation between CSF levels of 24S-OHC and total tau (t-tau) (A) and phospho-
tau (p-tau) (B) protein in patients with mild cognitive impairment (MCI) and Alzheimer's 
disease (AD).  
 
Based on the measurements in the controls, a 95% confidence interval was defined 
for the CSF 24S-OHC. The highest cut-off value, corresponding to the 95th percentile 
of the 24S-OHC distribution, was calculated to be >3.0 ȝg/L to distinguish normal 
from pathological values. The cut-off values for the CSF markers were set according 
to what has been published in the literature (64, 65); t-tau protein (>300 ng/L in the 
group 21–50 years of age, >450 ng/L in the group 51–70 years of age, and >500 ng/L 
in the groups 71–93 years of age), p-tau (>65 ng/L) and Aȕ42 (<500 ng/L). Individual 
values for each patient were compared with the cut-off levels. 
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In the AD patients, the percentage of subjects with increased levels of 24S-OHC 
(67%), t-tau (61%), p-tau (69%) and decreased Aȕ42 (56%) were similar. In the case 
of MCI, 50% of the patients had increased CSF levels of 24S-OHC, whereas the 18% 
and 29% of this population had increased levels of t-tau and p-tau, respectively. 
Decreased levels of Aȕ42 were found in one of the MCI patients (Figure 14). 
 
 
Figure 14. Proportion of the patients in the different diagnostic groups with pathological levels 
of the markers in CSF. The proportion was calculated as the number of subjects with increased 
or decreased values divided by the number of subjects in each group and expressed in 
percentage. For 24S-hydroxycholesterol (24S-OHC) the upper cut-off value was calculated as 
the 95th percentile value in the control group (3 ȝg/L). The cut-off values of t-tau, p-tau and 
Aȕ42 were taken from the literature. t-tau > 300 ng/L (21–50 years) or 450 (51–70 years) or 
500 ng/L (71–93 years); p-tau > 65 ng/L and Aȕ42 < 500 ng/L. 
 
 
In previous work (93) it was found that neuronal damage causes increased CSF levels 
of 24S-OHC, and that a dysfunction of the blood–brain and blood–CSF barriers 
results in increased levels of 27-OHC. In this study, significantly increased levels of 
both 24- and 27-OHC were found in patients diagnosed with AD and MCI (the two 
group of patients studied), compared to controls. 
Furthermore, in both groups we found that in a high fraction of patients the levels of 
24S-OHC were increased over the set cut-off. The high fraction of MCI patients with 
increased CSF 24S-OHC (50%), as compared with the smaller number of the same 
patients with a significant alteration of the levels of the other markers, is consistent 
with the possibility that 24S-OHC might be used as a new biomarker for ongoing 
neurodegeneration in the evaluation of patients with MCI. Whether or not elevated 
values can predict development into AD has to be evaluated in longitudinal studies 
where the conversion from MCI to AD must be assessed. The MCI cohort used in the 
present study was diagnosed according to the latest criteria suggested by Winblad et 
al. (164). It should be emphasised that the MCI group is heterogeneous and this 
heterogeneity might explain the non-Alzheimer distribution of APOE4.  
The level of CSF t-tau is regarded to reflect the degree of neuronal degeneration and 
damage. In addition to indicating neuronal damage, CSF p-tau is believed to reflect 
phosphorylation of tau and thus formation of neurofibrillary tangles (167). 
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As expected, the “neuronal” 24S-OHC, a supposed marker of ongoing neuronal 
destruction was found to be significantly positively correlated with both t-tau and p-
tau both in patients with AD and with MCI. Interestingly, there was no such 
correlation between the CSF level of 27-OHC and the other markers, in accordance 
with the contention that most of the 27-OHC present in CSF originates from the 
circulation rather than from the brain (149, 162). 
However, the levels of 27-OHC were found to be significantly increased in both MCI 
and AD patients as compared to the controls, in according with a previous report 
(100). The enzyme responsible for the synthesis of the 27-OHC, the CYP27A1 has 
been found to be expressed in the brain, but 27-OHC was found to be 10% of the 
levels of 24S-OHC (166). The increased levels of 27-OHC may be due to dysfunction 
in the blood–brain and blood–CSF barriers. It has been reported that patients with AD 
may have a BBB or blood–CSF barrier dysfunction (163). Why this was also present 
in MCI subjects is not clear. It might reflect that MCI subjects may have brain 
disorders such as pre-AD and or cerebro-vascular disorders. Another possible 
explanation is that an increased flux of 24S-OHC as a result of neurodegeneration 
may have an inhibitory effect on the metabolism of 27-OHC as suggested by the 
results present in paper IV.  
The increase in levels of 24S-OHC in CSF of patient with neurodegeneration must be 
discussed in relation to the fact that the plasma levels of the same oxysterol are 
decreased in the same patients. More than 99% of the 24S-OHC fluxing from the 
brain to the circulation passes the blood brain barrier and less than 1% passes via 
CSF. Most of the 24S-OHC present in the CSF is bound to APOE. Dying neuronal 
cells release cholesterol that will be “cleaned up” by the glial cells. Because of 
CYP46A1 induced in the latter cells, there will probably be a local elevation in the 
concentration of 24S-OHC that may stimulate synthesis and release of APOE from 
the astrocytes. The most important elimination of APOE from the brain is likely to be 
through cerebrospinal fluid. For this reason, there may be a preference for elimination 
of 24S-OHC from dying neuronal cells through cerebrospinal fluid, and it is possible 
that the local increase of APOE may be a driving force for this. The correlation 
between APOE and 24S-OHC in CSF from patients with AD and MCI but not in CSF 
from controls (paper V) is in accordance with this.    
In conclusion, the CSF levels of 24S-OHC in this population of subjects indicate that 
24S-OHC might be a specific marker of MCI. The present pilot study on a small 
number of patients does not allow an accurate calculation of diagnostic sensitivity and 
specificity. The significance of 24S-OHC as a marker has to be further tested in 
longitudinal studies where the conversion to AD is assessed in the MCI group. The 
relation between pre-clinical AD and high levels of CSF 24S-OHC will be evaluated 
including calculations of sensitivity and specificity. 
The putative diagnostic and prognostic value of CSF 24S-OHC must also be 
compared with the corresponding values of t-tau, p-tau and Aȕ42. 
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Concluding remarks 
 
The present thesis focuses on the regulation of the neuronal-specific enzyme 
cholesterol 24S-hydroxylase, the enzyme responsible for conversion of cholesterol 
to 24S-hydroxycholesterol. The regulatory role of 24S-OHC in cholesterol 
homeostasis in the brain has also been studied. 
A related aim was to investigate the possible use of 24S-OHC as a marker for 
neurodegeneration. The following questions were addressed in the thesis and the 
results and conclusions are summarized below. 
 
      Is there a regulation of CYP46A1 at the epigenetic level? 
CYP46A1 has proved resistant to previous attempts to modulate its expression with 
treatments known to modulate various signalling pathways of importance for 
cholesterol balance. In the present work we tested the possibility that epigenetic 
factors are of importance for its expression. We could demonstrate both in vivo and 
vitro that the histone deacetylase inhibitors Valproate and Trichostatin A induce the 
expression of CYP46A1, essentially reprogramming non-neuronal cells to express 
CYP46A1 to the same level as that found in adult neurons. These findings suggest 
that it is possible to modulate CYP46A1 in the brain by pharmacological means.  
 
Is the drug Voriconazole also an inhibitor of CYP46A1 in vivo? Does the use of this 
drug cause changes in brain cholesterol homeostasis? 
The crystal structure of CYP46A1 was recently determined and it was shown that 
several compounds can inhibit CYP46A1 in vitro. One of the most potent inhibitors 
found was the antifungal drug Voriconazole, which has the reported side effects of 
visual disturbances. As this drug is known to be able to enter the brain and as 
CYP46A1 is expressed in the retina, we hypothesised that inhibition of CYP46A1 
may have a role in the reported side effects. Treatment of mice with Voriconazole 
led to a decrease in the concentration of 24S-OHC in the brain and a reduction in 
the lathosterol:cholesterol ratio, an index of brain cholesterol synthesis. In this 
connection it is of interest that in preliminary work pathological electroretinograms 
have been recorded from mice with a knockout of CYP46A1. 
 
Is there a dietary regulation of CYP46A1 by omega-3 fatty acids? 
Polyunsaturated fatty acids are essential structural components of the central 
nervous system and are of importance for learning and memory. A high ratio 
between omega-3 and omega-6 fatty acids seems to be an advantage. Two diets 
simulating the recommendations of the American Heart Association to increase the 
intake of n-3 polyunsaturated fatty acids were tested on Golden Syrian hamsters. 
CYP46A1 mRNA levels were increased in the liver and brain. There was a trend to 
increased cholesterol turnover in the brain as indicated by the slightly increased 
levels of lathosterol and 24S-OHC but unchanged levels of cholesterol. Increased 
CYP46A1 mRNA level is in line with the results of many human studies indicating 
that fish consumption or intake of n-3 polyunsaturated fatty acids have beneficial 
effects on brain function. 
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What are the metabolic consequences of an upregulation of CYP46A1? 
In order to test the hypothesis that increased formation of 24S-OHC is 
neuroprotective and learn more about the regulatory importance of this oxysterol, 
transgenic mice overexpressing human CYP46A1 were generated and 
characterized. CYP46A1 mRNA levels were detected in the following organs: 
brain, eye, ovary, testis, kidney, lung and liver. Significant levels of CYP46A1 
protein were however found only in brain, testis and eye with more than 10-fold 
higher levels in the brain than in the other organs. The circulating levels of 24S-
OHC were increased by a factor of 4-6 and the fecal excretion of this steroid in free 
form was increased more than 20-fold. In the brain of the overexpressing mice the 
total amount of CYP46A1 protein was increased 2-4 fold and the expressed human 
enzyme protein had the same cellular distribution as the endogenous enzyme. The 
level of 24S-OHC in the brain was about double that of the wildtype. Increased 
activity of CYP46A1 would be expected to consume cholesterol with subsequent 
increased synthesis. In accordance with this brain levels of lathosterol and other 
cholesterol precursors were significantly increased. Under in vitro conditions 24S-
OHC is an efficient activator of LXR. The overexpression did not however cause 
significant upregulation of LXR target genes in brain or liver. Whether or not 
overexpression of CYP46A1 has a protective effect in the activity on 
neurodegeneration and amyloid accumulation in the brain (in vivo) remains to be 
investigated. 
 
An interaction between 24S-OHC and APOE has been demonstrated in vitro. Is 
there a correlation between APOE and 24OHC in cerebrospinal fluid? 
 
One of the earliest observations to link cholesterol homeostasis with 
neurodegenerative diseases was the recognition that the H4 isotype of APOE is an 
important risk factor for late-onset Alzheimer’s disease. Recent in vitro work 
suggests that 24S-OHC may stimulate APOE transcription, protein synthesis and 
secretion. In light of this data, we hypothesised that there could be a correlation 
between the concentration of APOE and 24S-OHC in cerebrospinal fluid. In 
support of this hypothesis we found a significant such correlation in patients with 
AD and MCI, but not in the control group. The results are consistent with a close 
coupling between the formation and release of 24S-OHC and APOE secretion 
under conditions of ongoing neurodegeneration. 
 
Can levels of 24S-OHC in CSF be used as a marker for neurodegeneration? 
 
Given the above correlations, we investigated if the 24S-OHC in the cerebrospinal      
fluid is an early marker for AD. In support of our hypothesis, we could show that the  
cerebrospinal fluid content of 24S-OHC is at least as sensitive a marker for 
neurodegeneration in patients with AD as the accepted biomarkers (167) (i.e. 
tau,phospho-tau and ȕ-amyloid). The significance of 24S-OHC as an early marker 
for neurodegeneration is now further tested in longitudinal studies.  
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